1 A Phase  II, Double -Blind,  Randomized,  Placebo -Controlled,  Multicenter Trial to  
Assess  the Safety  and Efficacy  of 5% Monolaurin  Vaginal  Gel Administered  
Intravaginally  for the Treatment of  Bacterial  Vaginosis  
DMID  Protocol  Number: 12 -0021  
DMID Funding Mechanism: VTEU Contract  Support   
Pharmaceutical Support Provided by:  [CONTACT_881620]:  None  
IND Sponsor:  Division  of Microbiology  and Infectious Diseases  
The National Institute of  Allergy  and Infectious Diseases  
The National Institutes  of Health  
Principal Investigator:  [INVESTIGATOR_881571],  MD 
DMID Clinical Project Manager:  Barbara  Hahn, RN, BSN  
DMID Medical Monitor:  Soju Chang, MD  
Version  8 
23 May 2017  
DMID Protocol No. 12 -0021   Version  8.0 23May2017   
2  STATEMENT OF COMPLIA NCE  
 
This trial will be conducted in compliance with the protocol, International Conference  on 
Harmonisation  guideline E6:  Good  Clinical Practice:  Consolidated  Guideline, the applicable  
regulatory  requirements  from US Code  of Federal  Regulations  (CFR) (Title  45 CFR Part  46 and 
Title 21  CFR including Parts  50 and  56) concerning informed  consent and  Institutional Review  
Board regulations, and  the NIAID  Clinical Terms  of Award.  
All individuals  responsible  for the design  and conduct  of this study  have completed Human  
Subjects  Protection  Training  and are qualified to  be conducting this  research prior to  the 
enrollment of any subjects.  Curricula vitae  for all investigators  and sub-investigators  participating  
in this trial are on  file in a  central  facility  (21 CFR 312.23  [a] [6] [iii]  [b] edition).  
DMID Protocol No. 12 -0021   Version  8.0 23May2017   
3  SIGNATURE  [CONTACT_881683], and provides  the 
necessary  assurances  that this  trial will be conducted according  to all stipulations  of the protocol, 
including all statements  regarding confidentiality,  and according to local legal and  regulatory  
requirements  and applicable US  federal regulations  and ICH guidelines.  
 
 
Site Investigator:  
Signed:   Date:  
Name  
[CONTACT_881684]. [ADDRESS_1232546] OF  ABBREVIATIONS  ................................ ................................ ................................ ..... 9 
PROTOCOL SUMMARY  ................................ ................................ ................................ ........  12 
1. KEY  ROLES  ................................ ................................ ................................ ..........  15 
2. BACKGROUND  INFORMATION  AND  SCIENTIFIC  RATIONALE  ...................  17 
2.1. Background  Information  ................................ ................................ .........................  17 
2.1.1.  Monolaurin  (GML)  ................................ ................................ ................................ . 19 
2.2. Rationale  ................................ ................................ ................................ ................  23 
2.3. Potential  Risks  and Benefits ................................ ................................ ....................  23 
2.3.1.  Potential Risks  ................................ ................................ ................................ ........  23 
2.3.2.  Known Potential Benefits  ................................ ................................ .......................  24 
3. OBJECTIVES  ................................ ................................ ................................ ........  25 
3.1. Study  Objectives  ................................ ................................ ................................ ..... 25 
3.2. Study  Outcome  Measures  ................................ ................................ .......................  25 
3.2.1.  Safety  Outcomes  ................................ ................................ ................................ ..... 25 
3.2.2.  Efficacy  Outcomes ................................ ................................ ................................ .. 26 
[IP_ADDRESS].  Primary  and Secondary  Efficacy  Outcomes  ................................ ............................  26 
[IP_ADDRESS].  Exploratory  Efficacy  Outcomes  ................................ ................................ ..............  26 
4. STUDY  DESIGN  ................................ ................................ ................................ ... 27 
4.1. Substudies  (if applicable)  ................................ ................................ ........................  [ADDRESS_1232547]  Exclusion  Criteria  ................................ ................................ .......................  29 
5.3. Treatment  Assignment  Procedures  ................................ ................................ ..........  31 
5.3.1.  Randomization Procedures  ................................ ................................ .....................  31 
5.3.2.  Masking Procedures  ................................ ................................ ...............................  31 
5.3.3.  Reasons  for Withdrawal ................................ ................................ ..........................  32 
5.3.4.  Handling of Withdrawals  ................................ ................................ ........................  32 
DMID Protocol No. 12 -0021   Version  8.0 23May2017   
5  5.3.5.  Termination of Study  ................................ ................................ ..............................  33 
6. STUDY  INTERVENTION/INVESTI GATIONAL  PRODUCT  ...............................  [ADDRESS_1232548]  Description  ................................ ................................ ......................  34 
6.1.1.  Acquisition  ................................ ................................ ................................ .............  34 
6.1.2.  Formulation, Packaging,  and Labeling  ................................ ................................ .... 34 
[IP_ADDRESS].  5% Monolaurin  Vaginal Gel  ................................ ................................ ...................  35 
[IP_ADDRESS].  Vehicle  Placebo  Gel ................................ ................................ ...............................  [ADDRESS_1232549] Storage and  Stability  ................................ ................................ ..................  35 
6.2. Dosage,  Preparation  and Administration of Study  Intervention/Investigational 
Product  ................................ ................................ ................................ ...................  35 
6.3. Modification of  Study  Intervention/Investigational  Product  for a Participant  ..........  36 
6.4. Accountability  Procedures  for the  Study  Intervention/Investigational 
Product(s)  ................................ ................................ ................................ ...............  [ADDRESS_1232550]  Compliance  with Study  Intervention/Investigational 
Product  ................................ ................................ ................................ ...................  36 
6.6. Concomitant  Medications/Treatments  ................................ ................................ ..... 37 
7. STUDY  SCHEDULE  ................................ ................................ ..............................  38 
7.1. Screening  and Enrollment  (Visit 1,  Day 1) ................................ ..............................  38 
7.2. Visit  2 (Day  8 [Window: Days  8-15]) ................................ ................................ ..... 41 
7.3. Visit  3, Final  Study  Visit  (Day  28 [Window: Days  22-31]) ................................ ...... 42 
7.4. Early  Termination  Visit  ................................ ................................ ..........................  43 
7.5. Unscheduled Visit  ................................ ................................ ................................ .. 43 
8. STUDY  PROCEDURES/EVALUATIO NS ................................ .............................  45 
8.1. Clinical  Evaluations  ................................ ................................ ................................  45 
8.2. Laboratory  Evaluations  ................................ ................................ ...........................  45 
8.2.1.  Clinical  Laboratory  Evaluations  ................................ ................................ ..............  45 
8.2.2.  Special  Assays  or Procedures  ................................ ................................ ..................  46 
8.2.3.  Specimen Preparation, Handling, and  Shippi[INVESTIGATOR_007] ................................ .......................  47 
[IP_ADDRESS].  Instructions  for Specimen  Preparation, Handling,  and Storage  ................................  47 
[IP_ADDRESS].  Specimen Shipment  ................................ ................................ ................................  [ADDRESS_1232551]  Values  
or Abnormal Clinical  Findings  ................................ ................................ ................  52 
9.3. Reporting Procedures  ................................ ................................ .............................  53 
9.3.1. Adverse  Events  ................................ ................................ ................................ ....... 53 
[IP_ADDRESS].  Serious  Adverse  Events  ................................ ................................ ..........................  53 
9.3.2.  Regulatory  Reporting  for Studies  Conducted Under DMID -Sponsored  IND ..........  54 
9.3.3.  Reporting of Pregnancy  ................................ ................................ ..........................  54 
9.4. Type  and Duration of  Follow -up of Subjects  after Adverse  Events  .........................  54 
9.5. Halting Rules  ................................ ................................ ................................ ..........  54 
9.6. Safety  Oversight  (ISM  plus DSMB)  ................................ ................................ ........  [ADDRESS_1232552]  ................................ ................................ ..........  55 
9.6.2.  Independent Safety  Monitor (ISM)  ................................ ................................ .........  56 
10. CLINICAL  MONITORING  ................................ ................................ ....................  57 
10.1.  Site Monitoring Plan  ................................ ................................ ...............................  57 
11. STATISTICAL  CONSIDERATIONS  ................................ ................................ ..... 58 
11.1.  Introduction  ................................ ................................ ................................ ............  58 
11.2.  Data  Analysis  Populations  ................................ ................................ ......................  58 
11.3.  Study  Objectives  and Endpoints  ................................ ................................ ..............  58 
11.4.  Study  Hypotheses  ................................ ................................ ................................ ... 59 
11.5.  Sample  Size Considerations  ................................ ................................ ....................  60 
11.6.  Planned Interim  Analyses  ................................ ................................ .......................  61 
11.7.  Final  Analysis  Plan ................................ ................................ ................................ . 62 
11.7.1.  Safety  Analyses  ................................ ................................ ................................ ...... 62 
[IP_ADDRESS].  Overview  of Safety Analyses  ................................ ................................ ..................  62 
[IP_ADDRESS].  Analyses of  Primary  and Secondary  Safety  Outcomes  ................................ ............  63 
11.7.2.  Efficacy  Analyses  ................................ ................................ ................................ ... 63 
[IP_ADDRESS].  Overview  of Efficacy  Analyses  ................................ ................................ ...............  63 
12. SOURCE  DOCUMENTS  AND  ACCESS  TO SOURCE  
DATA/DOCUMENTS  ................................ ................................ ...........................  65 
13. QUALITY  CONTROL  AND  QUALITY  ASSURANCE ................................ .........  66 
14. ETHICS/PROTECTION  OF HUMAN  SUBJECTS  ................................ .................  [ADDRESS_1232553]  ................................ ................................ .....................  67 
14.3.  Informed Consent  Process ................................ ................................ .......................  67 
14.4.  Exclusion of Women,  Minorities,  and Children  (Special  Populations)  ....................  [ADDRESS_1232554]  KEEPI[INVESTIGATOR_1645]  ................................ .....................  70 
15.1.  Data  Management Responsibilities  ................................ ................................ .........  70 
15.2.  Data  Capture  Methods  ................................ ................................ ............................  70 
15.3.  Types  of Data  ................................ ................................ ................................ .........  70 
15.4.  Timing/Reports ................................ ................................ ................................ ....... 70 
15.5.  Study  Records  Retention ................................ ................................ .........................  71 
15.6.  Protocol  Deviations  ................................ ................................ ................................  71 
16. PUBLICATION  POLICY  ................................ ................................ .......................  72 
17. LITERATURE  REFERENCES  ................................ ................................ ...............  73 
SUPPLEMENTS/APPENDIC ES ................................ ................................ ..............................  76 
APPENDIX  A: SCHEDULE OF  EVENTS  ................................ ................................ ...............  76 
APPENDIX B:  Toxicity  Table  ................................ ................................ ................................ .. 78 
APPENDIX C:  Female  Genital Grading  Table for  Physical  Exam  Findings  ...............................  [ADDRESS_1232555] OF TABLES  
Table  1: Laboratory examination of vaginal smears and the determination of the Nugent 
Score  ................................ ................................ ................................ ......................  18 
Table  2: Solicited events & grading  ................................ ................................ ......................  51 
Table  3: Bacterial Vaginosis:  Determination of Therapeutic Cure ................................ ........  59 
Table  4: Power to compare bino mial proportions using a two -sided level 0.05 Fisher’s 
Exact Test with a sample size of N = 90 (60 subjects in the 5% Monolaurin 
Vaginal Gel arm, 30 subjects in the Vehicle Placebo Gel arm) Conditions in 
which Power is ≥.80 are highlighted  ................................ ................................ ....... 61 
Table  5: Schedule of Events  ................................ ................................ ................................ . 76 
Table  6: Toxicity Table  ................................ ................................ ................................ ........  78 
Table 7: Female Genital Grading Table for Physical Exam Findings  ................................ .... [ADDRESS_1232556] OF FIGURES  
Figure  1: Schematic of Study Design  ................................ ................................ .....................  14 
Figure  2: Light Microscopy of unstained vaginal smear showing clue cell  .............................  [ADDRESS_1232557] OF  ABBREVIATIONS  
 
ACOG  American  College  of Obstetricians  and Gynecologists  
AGUS  Atypi[INVESTIGATOR_881572]/Adverse  Experience  
ALT  Alanine  Aminotransferase  
ASCUS  Atypi[INVESTIGATOR_881573], NIAID,  
NIH,  DHHS  
DSMB  Data  and Safety  Monitoring  Board  
eCRF  Electronic  Case  Report  Form  
ELISA  Enzyme -Linked  Immunosorbent Assay  
FDA  Food  and Drug  Administration  
FWA  Federal  Wide Assurance  
GCP  Good  Clinical  Practice  
GML  Glycerol  Monolaurate  
GRAS  generally  recognized  as safe 
HIPAA  Health  Insurance  Portability  and Accountability  Act 
HIV Human  Immunodeficiency  Virus  
HSIL  High Grade Squamous Intraepi[INVESTIGATOR_881574]’s  Brochure  
ICF Informed  Consent Form  
ICH International  Conference  on Harmonisation  
ICMJE  International  Committee  of Medical  Journal  Editors  
IDE Investigational  Device  Exemption  
IDES  Internet Data  Entry  System  
IEC Independent or Institutional  Ethics  Committee  
IL Interleukin  
IND Investigational  New  Drug  Application  
ISM Independent Safety  Monitor  
IRB Institutional  Review  Board  
DMID Protocol No. [ADDRESS_1232558]  
DMID Protocol No. 12 -0021   Version  8.0 23May2017   
11   
MedDRA
  Medical  Dictionary  for Regulatory  Activities  
MIP Macrophage  Inflammatory  Protein  
mITT  Modified  Intent -To-Treat  
MOP  Manual  of Procedures  
N Number (typi[INVESTIGATOR_122732])  
NDA  New  Drug  Application  
NF The National  Formulary  
NIAID  National  Institute  of Allergy  and Infectious  Diseases,  NIH,  DHHS  
NIH National  Institutes  of Health  
OCRA  Office  of Clinical  Research  Affairs, DMID,  NIAID, NIH,  DHHS  
OHRP  Office  for Human  Research  Protections  
OHSR  Office  for Human  Subjects  Research  
ORA  Office  of Regulatory  Affairs, DMID,  NIAID,  NIH,  DHHS  
PCR Polymerase  Chain  Reaction  
PI [INVESTIGATOR_881575]-Protocol  
QA Quality  Assurance  
QC Quality  Control  
SAE  Serious  Adverse  Event/Serious  Adverse  Experience  
SDCC  Statistical  and Data  Coordinating  Center  
SIV Simian  Immunodeficiency  Virus  
SOP Standard  Operating  Procedure  
TSST  Toxic  Shock  Syndrome  Toxin  
US United  States  
USP United  States  Pharmacopeia  
DMID Protocol No. 12 -0021   Version  8.0 23May2017   
12  PROTOCOL SUMMARY  
 
 
 
Title:  A Phase  II, Double -Blind,  Randomized,  Placebo -Controlled,  
Multicenter Trial  to Assess  the Safety  and Efficacy  of 
5% Monolaurin  Vaginal  Gel Administered  
Intravaginally  for the Treatment  of Bacterial  Vaginosis  
Phase:  II 
 
 
Population:  120 women,  18-50 years  old, with clinical  evidence  of bacterial  
vaginosis,  recruited  from  the community  around  the University  of 
Iowa  Hospi[INVESTIGATOR_881576] , Cincinnati  Children’s  Hospi[INVESTIGATOR_881577].  
Number  of Sites:  2 
Study  Duration:  [ADDRESS_1232559]  Participation  
Duration:   
4 weeks  
Estimated  Time  to 
Complete  Enrollment:   
12 months  
Description  of Agent  or 
Intervention:  5% Monolaurin  Vaginal  Gel administered  intravaginally  
or placebo  gel 
Objectives:  Primary  Objectives:  
 To assess  the safety  and tolerability  of 5% Monolaurin  
Vaginal  Gel compared  to Vehicle  Placebo  Gel (excipi[INVESTIGATOR_881578]).  
 To assess  the efficacy  by [CONTACT_881621] 5% 
Monolaurin  Vaginal  Gel compared  to Vehicle  Placebo  Gel 
at Visit  2. 
Secondary  Objectives:  
 To evaluate  the therapeutic  cure rate of 5% Monolaurin  
Vaginal  Gel compared  to Vehicle  Placebo  Gel at Visits  2 
and 3. 
 To evaluate  the clinical  cure rate of 5% Monolaurin  Vaginal  
Gel compared  to Vehicle  Placebo  Gel at Visit  3. 
 To evaluate  the changes  in Nugent’s  criteria  of vaginal  
bacterial  flora at Visits  2 and 3. 
DMID Protocol No. 12 -0021   Version  8.0 23May2017   
13   
 
 
Exploratory  Objectives:  
 To evaluate  the clinical  and therapeutic cure  rates of 5% 
Monolaurin  Vaginal  Gel compared  to Vehicle  Placebo  Gel 
for each subgroup  (first epi[INVESTIGATOR_881579]) at 
Visits  2 and 3. 
 To evaluate  quantitative  changes  in selected  bacterial  
species  at Visits  2 and 3. 
 
 To evaluate  the quantitative  changes  of Candida  spp ( in 
subjects  with Candida  spp. identified  at screening)  at Visits  
2 and 3 
 
Description  of Study  
Design:  This is a Phase  2, double -blind,  randomized,  placebo -controlled,  
multi -center trial  of 120 BV subjects  randomized  at a ratio of 2:[ADDRESS_1232560] article  (5% Monolaurin  Vaginal  Gel) or  
placebo  (Vehicle  Placebo  Gel) as  outpatient  therapy.   Each  
subject  will self-administer  intravaginal  gel twice  daily  for 3  
successive  days for a total of six doses.  There  will be three  
clinic  visits  over 31 days.  
 
DMID Protocol No. 12 -0021   Version  8.0 23May2017   
 
14 
 Schematic  of Study  Design:  
Figure  1: Schematic of Study Design  
 
 
 
Screened  and + Amsel  criteria  N=120  
 
 
 
 
Receive  5% 
monolaurin  gel N=80   
 
 
 
rrhea  or chlamydia  positive  
or Safety  Laboratory  = 
Grade  3 
 
 
 
   
 
HIV, gonorrhea  or 
chlamydia  positive  or 
Safety  Laboratory  = 
Grade  3 
 
  
HIV, gonorrhea and  
chlamydia  negative  and 
Safety  Laboratories  < 
Grade  3 
  
 
Follow  for safety  and 
efficacy   
  
Stop study  drug and follow  
for safety  and efficacy  Stop study  drug and follow  
for safety  and efficacy  Follow  for safety  and 
efficacy  
 Receive vehicle 
placebo  gel N=40  
HIV, gonorrhea  or 
chlamydia  positive  or 
Safety  Laboratory  = 
Grade  3 
 HIV, gonorrhea and  
chlamydia  negative  
and Safety  
Laboratories  < Grade  3 
 Receive  5% 
monolaurin  gel 
N=80  
 
 
DMID Protocol No.  12-0021   Version  8.0 23May2017  
 
15  1. KEY  ROLES  
 
 
Lead  Principal  Investigator:  [INVESTIGATOR_881571], MD University  
ofIowa  
University  of Iowa  Hospi[INVESTIGATOR_881576]   
[ADDRESS_1232561]  
Iowa  City,  IA [ZIP_CODE]   
Phone:  [PHONE_18238]  
Fax: [PHONE_18239]  
E-mail:  patricia -[EMAIL_10074]  
Site Investigator:  Lea Widdice, MD  
Cincinnati Children's Hospi[INVESTIGATOR_139761]  
[ADDRESS_1232562]  
Cincinnati, OH [ZIP_CODE]  
Phone: 513 -636-7413  
FAX: 513 -636-1129  
E-mail: [EMAIL_16768]  
Site Investigator:  Brenna L. Hughes, MD, MSCR  
Duke University School of Medicine  
[ADDRESS_1232563]  
Durham, NC [ZIP_CODE]  
Phone: 919 -668-0843  
FAX: 91 9-613-1550  
E-mail:[EMAIL_16769]  
 
DMID Scientific Lead:  Carolyn Deal, PhD  
Sexually Transmitted Diseases Branch  
DMID/NIAID/NIH  
[ADDRESS_1232564], Room 8E40  
Bethesda, MD [ZIP_CODE]  
Phone: 301 -402-0443  
E-mail: [EMAIL_16770]  
     
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
16   
DMID Medical Monitor:  Soju Chang, MD  
Office of Clinical Research Affairs (OCRA)  
DMID/NIAID/NIH  
[ADDRESS_1232565], Room 7E59  
Bethesda, MD [ZIP_CODE] -6603  
Phone: 240 -291-4178  
E-mail: [EMAIL_16771]  
 
 
DMID Clinical Project Manager:  Barbara Hahn, RN, BSN  
Sexually Transmitted Diseases Branch  
DMID/NIAID/NIH  
[ADDRESS_1232566], Room 8E49  
Bethesda, MD [ZIP_CODE] -6603  
Phone: 240 -627-3267  
E-mail: [EMAIL_16772]  
DMID VTEU  Project Officer  Suzanne  Murray,  RN, BSN  
Office  of the Associate  Director of Clinical  
Research  
DMID/NIAID/NIH  
[ADDRESS_1232567],Room  7G25  
Bethesda, MD [ZIP_CODE]  
Phone:  [PHONE_18240]  
E-mail:  [EMAIL_16773]  
 
Statistical  and Data  Management Center  The Emmes  Corporation  Point  of 
Contact: [CONTACT_881622]  
[ADDRESS_1232568]., Suite  700 
Rockville,  MD [ZIP_CODE]  
Phone:  [PHONE_2269]  
Fax: [PHONE_16069]  
E-mail:  [EMAIL_16774]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
17  2. BACKGROUND  INFORMATION  AND  SCIENTIFIC  RATIONALE  
2.1. Background  Information  
Bacterial  Vaginosis  
Bacterial Vaginosis  (BV) is  a disease of the vagina caused by [CONTACT_50904].  Current  studies  suggest  
that BV is  caused by  [CONTACT_881623] a 
paucity  of hydrogen peroxide -producing lactobacil li and high concentrations  of facultative  
anaerobic  organisms  such as Gardnerella vaginalis , Mycoplasma hominis , Bacteroides  species,  
and others [ 1]. In women  of childbearing age, BV is the most common  cause of vaginitis  
accounting for 22 -50% of women  who have symptoms  of vaginitis  [2]. In a cohort of young  
healthy  women,  nearly  30% had been treated  for BV [ 3].  In American and  European studies, the 
prevalence  often  ranges  from 5 -36% with higher  prevalence  reported in women  attending  sexually  
transmitted disease clinics  [4]. 
BV has  been  associated  with preterm  delivery,  chorioamnionitis,  post-abortion  infection,  and 
pelvic  inflam matory  disease  [5-7]. 
Signs and Symptoms  
The most common  symptom of BV is  an abnormal  homogeneous  off-white vaginal discharge  
(especially  after sex)  with an unpleasant  smell.  On physical exam, the  discharge  often  coats  the 
walls  of the vagina, though  there is  relatively  little erythema, edema  or inflammation noted  on the  
vulva,  labia,  or the vaginal walls  [8].  Up to 50% of women  with BV are asymptomatic  [8]. 
Etiology  
A healthy  vagina normally  contains  many  microorganisms; some of the common  ones are 
Lactobacillus  crispatus  and Lactobacillus  jensenii .  Lactobacilli , particularly  hydrogen  peroxide - 
producing species,  appear  to help prevent  other vaginal microorg anisms  from multiplying  to a level 
where  they cause symptoms.  The microorganisms  involved  in BV are very  diverse,  but include  
Gardnerella vaginalis , Mobiluncus , Bacteroides , and Mycoplasma . A change  in normal  bacterial  
flora including the reduction of lactobacillus,  which  may be due  to the use of antibiotics  or pH 
imbalance, allows  more  resistant bacteria  to gain a  foothold  and multiply.  
Although  BV can  be associated with  sexual activity,  there is  no clear  evidence of sexual  
transmission  and it is possible  for sexually  inactive persons  to develop  BV [9].  Rather,  BV is  a 
disordering of the chemical  and biological balance  of the normal  flora.  A variety  of risk factors  
associated with BV have been identified  including a history  of smoking,  ethnicity,  intrauterine  
device use,  and douching [4,9]. 
Diagnosis  
The diagnosis  of BV has  been based  clinically  on Amsel and  more  recently  Nugent scoring  criteria 
using  direct Gram  stain of vaginal secretions.  
Amsel  criteria  
In 1983,  Amsel et al. established  clinical criteria  for diagnosing  BV [10]. To make  a diagnosis  of 
BV, a speculum exam  is performed  and a  swab from  inside  the vagina  is obtained.  The American  
College  of Obstetricians  and Gynecologists  (ACOG) clinical guidelines  state that three  of the four 
Amsel’s  criteria must  be positive to  warrant a diagnosis  of BV [2].  However,  the Food  and Drug  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
18  Adm inistration  (FDA) guidance  to industry  recommends  that subjects  in BV studies  should meet  
all four Amsel  criteria.  
o An abnormal  gray discharge.  
o Vaginal  pH greater than  4.5. 
o A positive  amine  test (often  called  a Whiff  test where  a characteristic  "fishy"  odor 
develops  after adding  a small  amount  of potassium  hydroxide  [10% KOH]  to a 
microscopic  slide containing  the vaginal  discharge).  
o ≥ 20% of the epi[INVESTIGATOR_881580]  
(Clue  cells).  
Figure  2: Light Microscopy of unstained vaginal smear showing clue cell  
    
Nugent  criteria  
In 1991,  Nugent  et al. described a  Gram stain scoring system of vaginal smears  to diagnose BV  
[11]. The Nugent  score  is calculated by  [CONTACT_881624] -positive rods  
(Lactobacillus morphotypes), small Gram -variable rods  (G. vaginalis  morphotypes),  and curved  
Gram -variable rods  (Mobiluncus  spp. morphotypes).  The Nugent score  can range  from [ADDRESS_1232569]  method  for diagnosis  of 
BV [12]).  Scoring  is as follows:  
Table  1: Laboratory examination of vaginal smears and the determination of the Nugent 
Score  
N Score  = The sum of the scores  for each bacterial  morphotype  listed  below.  (Note:  Number  of Organisms  
seen/high  power  field as determined  by [CONTACT_85719]  a representative  field by [CONTACT_881625])  
Lactobacilli  SCORE  Gardnerella,
Bacteroides  SCORE  Curved  gram -negative  
bacilli  SCORE  Sum=  
*N SCORE  
≥30 0 0 0 0 0 0 
<30-5 1 <1 1 <1 1 3 
<5-1 2 1 to <5 2 1 to <5 1 5 
<1 3 5 to <30 3 5 to <30 2 8 
0 4 ≥30 4 ≥30 2 10 
 
 

DMID Protocol No. 12 -0021   Version  8.0 23May2017  
19  Current  Treatments  
The Centers  for Disease  Control and  Prevention (CDC)  recommends  metronidazole  500 mg  orally  
twice daily  for 7 days,  intravaginal  metronidazole gel 0.75%  once  daily  for 5 days or clindamycin 
cream  2% intravaginally  once daily  for [ADDRESS_1232570] line therapy  for BV [9]. 
Alternative regimens  using  oral tinidazole,  oral clindamycin or  clindamycin ovules  are also  
provided.  However,  up to 30% of women  will have recurren t BV within 3 months  of therapy [13]. 
Frequent emergence  of vaginal candidiasis  results  from antibiotic  suppression of vaginal  flora,  and 
Candida species  are frequent commensal  organisms  in vaginal  flora.  Given BV’s  high recurrence  
rates  and the risks for antimicrobial  resistance, additional treatment options  are desirable.  
2.1.1.  Monolaurin  (GML)   
Monolaurin  (GML)  
Monolaurin,  also commonly  referred  to as glycerol  monolaurate  (GML),  is a monoglyceride  
surfactant . It is an ester formed  from glycerol  and lauric  acid.  Laboratory  studies  have shown  that 
GML  has antibacterial,  antifungal  and antiviral  properties.  
GML Mechanism  of Action  
Several published studies  indicate  that monolaurin’s  primary  mechanism  of action is  the insertion 
of its fatty acid 12-carbon  chain into  the microorganism’s  plasma  membrane thus  interfering with 
plasma  membrane  signal transduction and  transcription  [14-19]. 
In addition  to its direct effects  on pathogens, monolaurin stabilizes  animal and human  cell 
membranes  to interfere  with the  damaging effects  of bacterial exotoxins, endotoxins,  and hypotonic  
solutions,  including  reduction  of chemokines  (interleukin  [IL]-8, macrophage  inflammatory  protein  
[MIP] -3α) that cause vaginal inflammation [ 15,19,20]. This property  is advantageou s in the  
prevention  of infection  transmission [20]. Typi[INVESTIGATOR_897],  agents  that cause  vaginal inflammation 
promote  transmission of sexually  transmitted infections  such as human  immunodeficiency  virus  
(HIV) [21-24]. 
A study  at the  University  of Minnesota demonstrated that GML’s  action occurs  at the  
 
(Schlievert  unpublished  data).  
Monolaurin’s  mechanism of action  of blocking signals  at the  pathogen’s  plasma  membrane  
provides  an advantage  over other antibiotics  with regard  to the development  of resistance. The  cell 
walls  of bacteria have 10-20 two-component membrane  signaling systems  that can  all be  targeted 
by [CONTACT_881626]  [14, 25]. This high number of targets  suggests  that it may be more  difficult  for bacteria  to 
develop  resistance to  monolaurin.  Two published studies  demonstrate  that bacteria  with long -term 
exposure  to sub -inhibitory  concentrations  of GML remain  sensitive to its  bactericidal properties.  
Petschow  et al. investigated  the susceptibility  to metronidazole,  tetracycline,  and monoglycerides  
(including monolaurin)  to three  test strains  of Helicobacter  pylori.  The frequency  of resistance of 
variants  to either metronidazole  or tetracycline when  tested  at five times  the minimum  inhibitory  
concentration was 10-5 to 10-7, whereas  no resistant  variants  of Helicobacter  pylori were found  for 
any of the monoglycerides  tested [ 26].  Schlievert  et al. did not observe  any increase in resistance  
to GML’s  antimicrobial and anti-exotoxin effects  with yearlong  passage of Staphylococcus aureus 
MN8 on sub -growth -inhibitory  concentrations  of GML [ 25]. 

DMID Protocol No. [ADDRESS_1232571] ~40  pathogenic  vaginal  
organisms,  including bacteria, yeasts, protozoa,  and viruses  [25].  Bacterial organisms  studied  
included  Gardnerella vaginalis , Bacteroides  fragilis , Mycoplasma hominis , various  Streptococcus  
spp., Neisseria gonorrhoeae , Escherichia coli,  and others.  GML was effective in  inhibiting  the 
growth of all potentially  pathogenic Candida  species  (11 strains  of Candida  albicans  were  tested  in 
vitro  as well as one strain  of each of four other  major  Candida  species)  providing for the potential 
to treat pathogenic fungal infections  in the vagina.  Since  Candida  is also controlled by  [CONTACT_881627], 
fungal overgrowth  secondary  to antibiotic  therapy  should not  occur.  Additionally,  lactobacilli,  as 
normal vaginal microflora,  are not significantly  affected  by [CONTACT_881628].  For the microorganisms  relevant  to the proposed  indication,  the highest 
minimum microbicidal concentration of monolaurin was 500 µg/mL,  which  is 100-fold lower  than 
the concentration of monolaurin  in the  proposed  drug product  (50 mg/mL).  
Additionally,  Li et al. demonstrated  that 5% Monolaurin Vaginal Gel prevents  transmission and  
infection of simian immunodeficiency  virus  (SIV) in 12  rhesus  macaque  monkeys [ 20].  Peterson  
et al. showed  that GML (250  µg/0.25  mL), when  co-administered vaginally  to rabbits  with toxic  
shock  syndrome  toxin -1 (TSST -1), completely  prevented TSST -1-induced  Toxic  Shock  Syndrome 
after 24 hours [15]. 
In addition  to its broad and appropriate antimicrobial activity,  monolaurin  has been shown  in vitro  
to reduce  the production of inflammatory  cytokines  by [CONTACT_881629][INVESTIGATOR_881581]  T 
and B  cells in response to  superantigen  and antigen  stimulation,  and to  protect  mammalian cells  
from  exotoxin.   In vivo  studies  in rhesus  monkeys  and humans  have shown  that monolaurin,  but not 
vehicle control,  significantly  reduces  cytokine production.  
In summary,  monolaurin  has been shown  to have important  antimicrobial effects  on pathogens  
found vaginally  in women.   In addition, monolaurin also inhibits  the production of exotoxins  by 
[CONTACT_881630] -induced  
inflammation.  The compound does  not affect lactobacilli,  the normal  flora of the human vagina.  
Finally,  the breadth  of antimicrobial activity  suggests  that the adverse  event  (AE)  of vaginal  
microbial overgrowth of other microorganisms  is highly  unlikely.  
Pharmacokinetics  (PK)  
There have been no  formal PK studies  of Monolaurin  Vaginal Gel in animals  or humans  to date. 
However  it is believed  that monolaurin systemic  absorption will be minimal,  and any monolaurin  
absorbed across  the vaginal  wall would  be quickly  metabolized by  [CONTACT_881631],  or re -esterified to a  triglyceride, all common  compounds  found in dietary  fats and lipi[INVESTIGATOR_805]  
[27]. There is  no evidence  that the presence  of monoglycerides  of food fats has any deleterious  
effect  on cells or tissues  [28].  Additionally, glyceryl monostearate, a 21  carbon  monoglyceride,  is 
approved for use as an excipi[INVESTIGATOR_881582] 17% (e.g., PREMARIN® 
Vaginal Cream).  
Phase 2 Clinical  Studies  using  Monolaurin Vaginal Gel  
The following  two clinical  studies  were  performed  at the University  of Minnesota, and were  
designed as single -center, double -blind device  clinical studies  using  Monolaurin  Vaginal  Gels 
containing up  to 5% monolaurin.  
 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
21   
 Device Clinical  Pi[INVESTIGATOR_52081]  (Protocol 2005 -024) – Status:  Completed  
A single -center, randomized,  double -blinded,  device  clinical pi[INVESTIGATOR_881583] 36  women  [29]. The objective was to determine  the effects  of an intravaginal  gel 
containing GML on vaginal Candida albicans , Gardnerella vaginalis , and Lactobacillus  spp. and  
to determine  GML persistence vaginally.  
The key endpoints  in the study  were  differences  in colony  counts  of Candida albicans,  
Gardnerella vaginalis,  and Lactobacillus  spp. between  vaginal swabs  taken before  (at Visit  1) and 
after use of the intravaginal gel at Visit 2, approximately  [ADDRESS_1232572] administration;  and 
differences  in GML amounts  vaginally  between swabs  taken  before and  after use of GML -
containing gel.  
The study  included non -pregnant women,  18-[ADDRESS_1232573] a 
vaginal infection.  Women were  administered 5  mL of gel containing  0%, 0.5% or 5% of GML  
every  [ADDRESS_1232574] gel administration and  12 hours  after the  final gel 
administration  for the  following tests:  vaginal pH,  wet mount and KOH  test, Gram staining,  yeast  
and bacterial cultures  (Candida albicans,  Gardnerella vaginalis,  and Lactobacillus  spp.) and GML 
measurement (Gas  Chromatograph -Mass  Spectroscopy assay).  Subjects  were  randomly  assigned  
to receive  one of the three  study products  (control, low or high concentration  of GML)  and were  
provided three  more  applications/doses  of the appropriate study  product  formulation  for self -
administration.  At about 12 hours  after the  final gel administration,  vaginal  swabs  were  again 
collected and  the same  tests performed.  
A total  of 36 women  were  analyzed  in this  study.  The numbers  of subjects  receiving gels  were  as 
follows:  control,  N=14;  0.5% monolaurin,  N=13;  and 5% monolaurin,  N=9.  
Results  compared  the prevalence  of the three study microorganisms, comparing Visit  1 to Visit  
Because of the small  numbers  of study  participants, data  for GML (0.5%  and 5%) were  evaluated 
individually  but also pooled  because  of sample size  for determination of significant  differences  
between  visits.  
The prevalence of Lactobacillus  between Visits  [ADDRESS_1232575]  on 
lactobacilli.  
Women  who received the 0.5% GML gels  showed significant reductions  in Candida  colony - 
forming units (CFU) between Visits  1 and 2  (P=0.001)  but not for the  5% GML (P=0.15)  due to 
sample size (6  at Visit  1, 2 at Visit  2). When  GML  treatment  groups  (0.5% and 5% GML)  were  
combined in  the analysis,  significant reductions  of both Candida  counts  between  Visits  1 and 2  
were  found  (P=0.015).  The reduction of Candida  in the GML  gel-treated  women  who showed  
reductions  between Visits  1 and  2 was nearly  to the minimum  level  of detection in  the analyses  (102 
CFU).  
A control  gel effect  was found  for women  with Gardnerella vaginalis .  Significant reductions  were  
seen in Gardnerella vaginalis  counts  between Visits  1 and 2  for women  who received the  control  
(P=0.006).  Women who received the 0.5%  and 5% gels did not individually  show  significant 
reductions  between  Visits  1 and 2, but when  GML treatment  groups  (0.5% and 5% GML)  were  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
22  combined in  the analysis,  the counts  of Gardnerella vaginalis  were  found  to be significantly  lower  
between Visits  1 and 2  (P=0.015).  
GML was detected vaginally  in the women  immediately  after initial application of the GML  gels 
(data  not shown); GML was not detected  (<0.7  µg/mL)  in women  who received  control  gels.  
GML was undetectable in women  during  the second visit,  regardless  of gel treatment, indicating  
that GML did not persist  in vaginal secretions  for the 12 hours  between  treatments.  No AEs were  
reported  by [CONTACT_881632].  
 Device Clinical  Safety  Study  of 5% GML Applied  Vaginally  – Status: Analysis and  
Final Report in  Preparation  
In this single -center,  double -blind,  parallel design, randomized  study  subjects  (HIV  negative,  
healthy,  non-pregnant women) receive once  vaginal 5% GML or  vehicle  
placebo gel  for  
The primary  objective of the study  is to determine the  safety  of  of vaginal  
GML  by [CONTACT_881633],  healthy  women  for  
  A secondary  objective is to determine  the tolerability  and acceptability  of a 5% GML  
vaginal gel.  
The primary  endpoint  of the study  is to assess  the effect of vaginal  GML on  
 
 
The secondary  endpoints  are as  follows:  
1) To assess  the effect  of GML  on  
 
2) To determine  the effect of vaginal  GML  on the as 
determined  by  
 
3) To determine  the acceptability  and tolerability  of vaginal  GML  based  on  
 
 
The protocol specifies  enrollment  of  women  ages 18-45,  
  At the time of enrollment, women are randomized to  either  the treatment  or placebo 
group.  The treatment group  receive a  vaginal applicator containing  either   
 or  
 
For both groups, vaginal  gels are administered  
 
Subjects  return  to clinic every  
  At Visits   
 
 
The primary  endpoint  is based on   A subject is  declared   
 

DMID Protocol No. [ADDRESS_1232576] is  required  to  
 The secondary  endpoints  are based  on  
 
 by [CONTACT_748].  
This study  is currently  in the process  of being reported  and results  may be used to power  definitive 
pi[INVESTIGATOR_881584] a New  Drug  Application (NDA)  filing.  
Initially,  7 women  were  enrolled and completed  the study. These women  consistently  reported  that 
 
 This 
was deemed  by [CONTACT_171579], and thus  
 
 
 
 The use of these   
 The 
study  has recently  been completed,  and the  data are presently  being  analyzed.   
 by [CONTACT_881632].  
Hereafter, the  gels referred to  in this  protocol will be identified as  5% Monolaurin  Vaginal  Gel, 
and Vehicle Placebo Gel,  which  has the same  formulation except  not containing  5% GML.  
2.2. Rationale  
Extensive  in vitro  data demonstrates the antimicrobial activity  of monolaurin on the  spectrum  of 
microorganisms  associated with BV,  while  having a  favorable effect  on eukaryotic  membrane  
stability  by [CONTACT_881634].  
New  therapi[INVESTIGATOR_881585]  5% Monolaurin  Vaginal Gel has  the potential to  eradicate  
flora associated with BV  while maintaining  some  of the normal  flora that is considered  protective  
for vaginal health, and with the added  potential of preventing the  emergence of vaginal  candidiasis.  
This study  is designed  to evaluate the  safety  and provide early  efficacy  in treatment of women  with 
BV. 
2.3. Potential Risks  and Benefits  
2.3.1.  Potential Risks  
There are no  known  safety  pharmacology  studies  of GML’s  effects  on the cardiovascular  and 
respi[INVESTIGATOR_63944].  However,  GML has  low systemic  absorption  making these toxicities  less 
likely.[ 27] 
The initial nonhuman primate  study  exposing rhesus macaque  monkeys  to 5% GML gel  (N=9),  or 
vehicle (N=3)  for 6 months  provided  evidence that  prolonged  gel exposure does  not induce  
inflammation, supported  by [CONTACT_881635].  GML reduced the  early  inflammatory  production of interleukin 8  by [CONTACT_881636][INVESTIGATOR_1663],  but the  quantitative aerobic  microflora did not differ between the  5% gel and  the 
control  gel, with no suppression of lactobacilli even with such prolonged  daily  exposure  [30]. 

DMID Protocol No. 12 -0021   Version  8.0 23May2017  
24  An initial study  in 36 women  exposed  to gels containing  0.5% (N=13),  5% (N=9),  or 0% (N=14) 
GML every  12 hours  for 2 days reported no AEs,  and no negative  effects  on lactobacilli,  while 
reducing Candida  and Gardnerella vaginalis  [29]. 
The only minor  side effect  noted was vaginal leakage.  
There  may be other side  effects  from GML,  even serious  ones that are not yet known . There  are no 
known risks  of GML to pregnant  women,  fetuses,  or infants  of breastfeeding  women.  The risks are 
thought to  be minimal due to  GML’s  low systemic  absorption. However,  the use of GML in 
pregnancy  or breastfeeding may  involve  risks to the subject,  fetus, or  nursing infant that  are 
currently  unforeseeable. This  study  will exclude pregnant  and breastfeeding  women  and ensure  that 
women  of childbearing  potential take  precautions  to avoid  pregnancy  during  the study.  
2.3.2.  Known Potential Benefits  
Participation  will contribute  to the knowledge about  the safety  and early  effects  of the treatment  on 
symptoms  of BV and the changes  in vaginal  flora.  Subjects  will receive a  gynecological  physical 
exam  and routine laboratory  tests to assess  their health  status.  
Society  may benefit  from the  potential development  of a new treatment for  BV. 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
25  3. OBJECTIVES  
3.1. Study  Objectives  
Primary  Objectives:  
 To assess  the safety  and tolerability  of 5% Monolaurin  Vaginal  Gel compared  to Vehicle  
Placebo  Gel (excipi[INVESTIGATOR_881586]).  
 To assess  the efficacy  by [CONTACT_881621] 5% Monolaurin  Vaginal  Gel compared  to 
Vehicle  Placebo  Gel at Visit  2. 
Secondary  Objectives:  
 To evaluate  the therapeutic  cure rate of 5% Monolaurin  Vaginal  Gel compared  to Vehicle  
Placebo  Gel at Visits  2 and 3. 
 To evaluate  the clinical  cure rate of 5% Monolaurin  Vaginal  Gel compared  to 
Vehicle  Placebo  Gel at Visit 3.  
 To evaluate  the changes  in Nugent’s  criteria  of vaginal  bacterial  flora at Visits  2 and 3. 
Exploratory  Objectives:  
 To evaluate  the clinical  and therapeutic cure rates of 5% Monolaurin  Vaginal  Gel compared  
to Vehicle  Placebo  Gel for each subgroup  (first  epi[INVESTIGATOR_881579]) at Visits  2 
and 3. 
 To evaluate  quantitative  changes  in selected  bacterial  species  at Visits  2 and 3. 
 To evaluate  the quantitative  changes  of Candida  spp (in subjects  with Candida  spp. 
identified  at screening)  at Visits  [ADDRESS_1232577]. Outcomes  will be reported by [CONTACT_2939]. 
 
 Primary  Safety  Outcome  – 
 Number  of subjects  reporting  solicited  urogenital  AEs following  the first dose 
of the study  product through  Visit  2 (Day  8-15). 
 Number  of subjects  reporting  serious  adverse  events  (SAEs) considered  product - 
related  following  the first dose of the study  product through Visit  3 (Day  22-31) 
 Secondary  Safety  Outcomes  – 
 Number  of subjects  experiencing  non-laboratory non -solicited  AEs following  the 
first dose  of the study  product  through  Visit  3 (Day 22 -31). 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
26   
 Number  of subjects  experiencing  laboratory  AEs following  the first dose of the 
study  product through Visit  2 (Day  8-15). 
3.2.2.  Efficacy  Outcomes  
[IP_ADDRESS].  Primary  and Secondary  Efficacy  Outcomes  
 
 Primary  Efficacy  Outcome  – Proportion  of subjects  with clinical  cure in each study  arm at  
Visit  2 (Day  8-15). 
 Secondary  Efficacy  Outcomes  – 
 Proportion  of subjects  with therapeutic  cure in each study  arm at Visit  2 (Day  8- 
15) and at Visit  3 (Day  22-31). 
 Proportion  of subjects  with Nugent score  of 3 or less (negative  for BV) and 4-6 
(intermediate) in  each study arm at Visit 2 (Day  8-15) and at Visit 3 (Day  22-31). 
 Proportion  of subjects  with clinical  cure in each study  arm at Visit 3 (Day  22-31). 
[IP_ADDRESS].  Exploratory  Efficacy  Outcomes  
 
 Proportion  of subjects  with clinical  cure in each study  arm by [CONTACT_6496]  (first time or 
recurrent infection)  by [CONTACT_4838]  2 (Day  8-15) and  by [CONTACT_4838]  3 (Day  22-31). 
 Proportion  of subjects  with therapeutic  cure in each study  arm by  [CONTACT_6496]  (first time  or 
recurrent infection)  by [CONTACT_4838]  2 (Day  8-15) and  by [CONTACT_4838]  3 (Day  22-31). 
 Mean  count  of Lactobacillus  spp., Gardnerella  spp., and  Mobiluncus  spp., respectively,  
in each study  arm at baseline,  Visit  2 (Day  8-15) and at Visit  3 (Day  22-31). 
 Mean  fungal colony  count  in vaginal  secretions  in each study  arm at baseline,  at Visit 2 
(Day  8-15) and  at Visit 3 (Day  22-31). 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
27   
4. STUDY  DESIGN  
This is a Phase  2, double -blind,  randomized,  placebo -controlled, multi -center trial enrolling  120 
subjects  with BV who will be randomized at a  ratio of 2:[ADDRESS_1232578]  article  (5% 
Monolaurin Vaginal Gel) or  placebo  (Vehicle Placebo  Gel).  There  will be three  clinic  visits  over 
[ADDRESS_1232579] evidence of BV using the Amsel  criteria 
(subjects  must  have any three of the four  Amsel criteria:   presence of discharge,  greater than  or 
equal to  20% clue cells on wet prep, positive “whiff test”  on KOH prep,  vaginal  pH of greater than  
4.5).  Vaginal  swabs  for Gram s tain of vaginal smear,  and assessment for Candida spp ., selected  
bacterial species,  Trichomonas  vaginalis,  Chlamydia trachomatis,  and Neisseria  gonorrhoeae will 
be collected . Those with clinical evidence of  active  genital ulcer  disease or evidence of 
trichomonas  on wet prep or OSOM® test will be excluded  from  the study.   Blood samples  will be 
collected  for safety  assessments  (HIV,  WBC  count,  hemoglobin,  platelets, neutrophil  count, 
creatinine,  aspartate aminotransferase [AST],  alanine aminotransferase [ALT], total bilirubin,  
random glucose).  Subjects  who continue  to qualify  for participation  will be randomized at a  ratio 
of 2:1 to  receive  5% Monolaurin  Vaginal Gel  or Vehicle Placebo  Gel administered  vaginally  
morning  and night for 6  consecutive doses  (3 days).   All subjects  will be provided a 5 -day memory  
aid to assess  for local solicited events with instruction on  use prior  to discharge.  The 
investigational  drug (active test  article or placebo) will be supplied in  a kit containing sufficient  
prefilled  vaginal applicators  for six consecutive doses  over [ADDRESS_1232580] will  be evaluated in  the clinic  at screening and  at Visit  2 (Day  8 [Window  Days  8-15]) 
and Visit  3 (Day  28 [Window  Days  22-31]) following  study  drug administration.  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
28  Visit  2 (Day  8 [Window  Days  8-15]):  At this  visit,  the study  team will review the  memory  aid, the  
intercurrent  medical history  with assessment  of AEs and SAEs, changes  to the  concomitant  
medications, a  gynecological exam  and a targeted physical exam  based on symptoms  will be 
performed,  and vaginal pH and vaginal swabs for Gram stain, saline wet mount, KOH  10% wet 
mount and culture  will be obtained . If signs  and symptoms  of vaginitis  fail to  resolve,  the study  
clinician  will refer the  subjects to  their clinician  for standard  treatment  for BV or  other etiologies  
of vaginitis  at the clinician’s  discretion and  the subject will be classified as  a clinical  failure at 
Visit  2 and/o r 3.  Follow -up hematology and  chemistry  labs (WBC  count, hemoglobin,  platelets,  
neutrophil count, creatinine,  AST, ALT, total bilirubin,  random glucose) for  safety  evaluation will  
be performed.  
Visit  3 (Day  28 [Window  Days  22-31]) will include a review  of the intercurrent medical history,  
concomitant medications,  AEs and SAEs, and  a gynecological exam  and a  targeted  physical  exam  
based on  symptoms.  Vaginal pH and  vaginal  swabs  for Gram stain,  saline wet mount,  KOH 10% 
wet mount and culture  will be performed.  
Subjects  who have positive HIV,  Chlamydia , or Neisseria gonorrhoeae, or a grade  [ADDRESS_1232581]  consents  to 
future use  of specimens.  
4.1. Substudies  (if applicable)  
None  
DMID Protocol No. [ADDRESS_1232582] meet all of the following inclusion 
criteria to  participate  in this  study:  
1. Non-pregnant,  non-breastfeeding  females  between  the ages of 18 and 50 years,  
inclusive.  
2. Women  of childbearing  potential* must  agree  to practice  reliable  contraception** 
for the 28-day period  before  enrollment  through  30 days following  treatment.  
*(not surgically  sterile  via tubal  ligation, bilateral  oophorectomy  or hysterectomy,  or 
who have not been postmenopausal  for ≥1 year)  
** Acceptable  birth control  methods  for the purposes  of this study  may include,  but are 
not limited  to, abstinence  from  intercourse  with a male  partner, monogamous  
relationship  with vasectomized  partner, barrier methods  to include  condoms  and 
diaphragms,  intrauterine  devices,  and licensed  hormonal  methods.   NuvaRing® 
contraceptive  use will be prohibited  from this  study  since  the device  can alter vaginal  
secretions.  
3. Presenting  with signs  of BV (as per Amsel  Criteria).   Subjects  must  meet  any 
three of the  four criteria  for enrollment*  
*Presence  of discharge, greater than  or equal  to 20% clue cells on wet prep,  positive  
“whiff  test” on  KOH  prep, vaginal  pH of greater  than 4.5. 
4. Not currently  menstruating  or expected  to in the next [ADDRESS_1232583] any of the following:  
 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
30  1. Signs  or symptoms  of vaginal/cervical/pelvic  infection  on screening or clinical 
diagnosis of vaginal/cervical/pelvic infection in the past 14 days.   
*(including  but not limited  to yeast  vulvovaginitis, chlamydia,  gonorrhea, trichomonas,  
genital  ulcer  disease,  pelvic  inflammatory  disease).  Self -treatment for presumed yeast 
vaginitis is not an exclusion if treatment was discontinue d [ADDRESS_1232584] 14 days.  
3. Cervical or vaginal high grade squamous intraepi[INVESTIGATOR_281226] (HSIL), atypi[INVESTIGATOR_881587] (AGUS) or cervical intraepi[INVESTIGATOR_881588] 2 (CIN2) or higher*  
*Atypi[INVESTIGATOR_145582] (ASCUS), low grade squamous 
intraepi[INVESTIGATOR_112716] (LSIL) or cervical intraepi[INVESTIGATOR_190502] 1 (CIN1) are 
acceptable. Individuals with a history of atypi[INVESTIGATOR_881589] 
(AGUS), HSIL or CIN2 and who have received subsequent evaluation and/or treatment 
with follow up normal PAP smear are eligible. Patient report will be accepted.  
4. History  of undiagnosed  vaginal  bleeding.  
5. Use of a systemic, vaginal,  or perineal  antibiotic  within  7 days prior to enrollment in  
this study.  
6. Use of an immunosuppressive  or immunomodulatory  drug*  for two or more  
consecutive  weeks  within  6 months  prior to enrollment  
*such  as >0.5 mg/kg/day  or ≥20 mg total dose/day  of prednisone  orally  or >800  μg of 
inhaled  beclomethasone  (nasal  and non-genital  topi[INVESTIGATOR_881590]).  
7. History  of allergic  reactions  attributed  to compounds  of similar chemical  or 
biologic  composition  to Monolaurin  Vaginal  Gel. 
8. Uncontrolled  concurrent  illness*.   Subjects  with  a history  of organ  or marrow  
transplant are  excluded.  
*Including,  but not limited  to, ongoing  or active  infection, active  liver, kidney  or 
autoimmune  diseases  (a history  of thyroid  disease  will be permitted  as long as the 
thyroid  disease  is now stable),  symptomatic  congestive  heart  failure, unstable  angina  
pectoris,  cardiac  arrhythmia,  or psychiatric  illness/social  situations  that would  limit 
compliance  with study  requirements.  
9. Acute  illness  within  [ADDRESS_1232585]  (per investigator’s  
discretion).  
10. Pregnant  women  and women  who are planning  to become  pregnant within  30 days 
after the final study  dose,  or women  who are breastfeeding.  
11. Immunosuppression  as a result of an underlying  illness  or treatment  or use of 
anticancer chemotherapy  or radiation  therapy  (cytotoxic)  within  the preceding  36 
months.  
12. Active  neoplastic  disease*  or a history  of any hematologic  malignancy.   Active  
neoplastic  disease  is defined  as neoplastic  disease  or treatment  for neoplastic  disease  
within  the past 5 years.  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
31  *(excluding  non-melanoma  skin cancer)  
13. Received  an experimental  agent* within  [ADDRESS_1232586]  to receive  an experimental  agent during  the 1 month  study  period.  
*(vaccine,  drug, biologic, device,  blood  product,  or medication)  
14. Any condition  that would  place  the subject  at an  unacceptable  risk of injury, render her  
unable  to meet the requirements  of the protocol, or that may  interfere  with successful  
completion  of the study.  
15. A history  of alcohol  or drug abuse* during  the previous  1 year that in  the opi[INVESTIGATOR_881591]  
*For  example, daily  excessive  alcohol  use or frequent  binge  drinking  as determined  by 
[CONTACT_093],  or daily  marijuana  use. 
5.3. Treatment  Assignment  Procedures  
Subjects, study site  and laboratory  personnel will be masked  to the treatment  assignments  of study  
subjects.  
5.3.1.  Randomization Procedures  
Subjects  will be randomly  assigned  to active  drug or placebo in a  2:[ADDRESS_1232587] of randomized treatment  assignments  will be prepared by  [CONTACT_881637]’s  Internet  Data  
Entry  System (IDES).  IDES will assign each  volunteer a  treatment code  from the list after  
demographic  and eligibility  data have been  entered into  the system.  A designated  individual  at 
each site  will be provided with a treatment  key, which  links  the treatment code to the actual  
treatment  assignment, which will be kept  in a secure place.  
Instructions  for use of the enrollment module are  included in the  IDES User’s  Guide.  Manual  
back-up randomization procedures  are provided in the  Manual  of Procedures  (MOP) for  use in  the 
event  that the site  temporarily  loses  access  to the  Internet  or the online  enrollment  system  is 
unavailable.  
5.3.2.  Masking Procedures  
The applicators of vaginal gels  will be selected by [CONTACT_881638]. 
The volunteers, the  study  personnel who perform study  assessments  after admini stration, data  
entry  personnel  at the  sites,  and laboratory  personnel will be masked to  treatment  assignment.  The 
Data and  Safety  Monitoring Board  (DSMB)  may receive data in aggregate and  presented  by 
[CONTACT_2948].  The DSMB  may be unmasked  to individual  study  treatment assignments,  as  
needed, to  adequately  assess  safety  issues.  Refer to  the MOP  for unmasking  procedures.  
DMID Protocol No. [ADDRESS_1232588]  may withdraw  or be withdrawn  from the  study  for the  following  reasons:  
 The subject withdraws  consent  
 The study  is terminated  
 For any reason  that, in the opi[INVESTIGATOR_1072],  precludes  the subject's  participation  in 
the study  
 The subject no  longer  meets  inclusion/exclusion  criteria  
 The subject develops  an SAE that warrants  withdrawal  
 Other  safety -related  reasons  at the discretion  of the Principal  Investigator (PI),  DMID  
Medical  Monitor,  DSMB,  or the subject  
Any subject who has received  at least one dose of study  drug will be continued in efficacy  and 
safety  follow -up, if the subject agrees.  
Subjects  who test positive  for chlamydia,  gonorrhea,  HIV, or are incidentally found to have a PAP 
result consistent with AGUS or HSIL,  or have a Grade  [ADDRESS_1232589] received  
one dose of study  drug. (PAP smears are not part of the study protocol, but may have been done 
outsid e of the study protocol by [CONTACT_423]’s provider. Patient report of PAP smear abnormalities 
may be accepted as a criterion for discontinuation of study product).  
If a subject  develops  a grade [ADDRESS_1232590]  agrees, study  procedures  (e.g., blo od sampling  for safety  and 
vaginal sampling)  may be continued.  
Subjects  may withdraw  from  participation in  the study  at any time.  If a subject  withdraws  or is 
withdrawn prior  to completion of the study,  the reason  for this  decision  must  be recorded in  the 
case report  forms  (CRFs).  Refer to Section 7.[ADDRESS_1232591] 
withdraws  from the study.  
5.3.4.  Handling of Withdrawals  
In the case of subjects  who fail to  appear  for a follow -up assessment, extensive  efforts  (i.e., 
documented  phone  calls and certified  mail)  should  be made  to locate or recall them,  or at least to 
determine their  health  status.  These  efforts  should be documented  in the subjects' records  and their 
health  status  documented  in the appropriate CRF. If  a subject  is withdrawn prior  to completion of 
the study, the subject will not  be replaced.  
 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
33  5.3.5.  Termination of Study  
The NIAID/DMID has  the right to  terminate  this study at any time.  Reasons  for terminating the  
study  may include,  but are not limited  to, the  following:  
 Incidence  or severity  of AEs indicating  a potential  health  hazard  
 Data  recording  is inaccurate  or incomplete  
 The Investigator  has not been adhering  to the protocol  or applicable  regulatory  guidelines  in 
conducting  the study  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
34  6. STUDY  INTERVENTION/INVESTI GATIONAL  PRODUCT  
6.1. Study  Product  Description  
Monolaurin  (GML)  
Monolaurin,  also commonly  referred  to as GML,  is a monoglyceride  surfactant .  It is an ester  
formed  from glycerol  and lauric  acid.  Monolaurin  Vaginal  Gel is a clear, colorless,  non-sterile  
glycol -based  gel for vaginal  administration.  
FDA  recognizes  monoglycerides,  such as monolaurin,  as direct food  substances  that are generally  
recognized  as safe (GRAS) (21  CFR 184.1505).   Monolaurin  is also considered  safe as an 
ingredient  in cosmetics  and tampons  (e.g., o.b.® optiBalance).   As stated,  monolaurin  is 
commercially  available  as a food grade  substance  from  several  suppliers.   HLS  will use  
 
 for the initial  Investigational  New  Drug  Application  (IND) phase  2 clinical  
trials.  
This formulation  promotes  rapid  drug distribution, as  well as adequate  coverage, throughout the  
vaginal  cavity.   The acidic  pH keeps  monolaurin  in its non-ionized  form  in the vagina.  
Monolaurin,  which  is practically  insoluble  in water,  is highly  soluble  in this formulation.  
Vehicle  Placebo  Gel 
The Vehicle Placebo  Gel utilizes  the same vehicle  formulation  as used in the Monolaurin  Vaginal 
Gel. 
6.1.1.  Acquisition  
5% Monolaurin  Vaginal  Gel and Vehicle Placebo  Gel will be provided by  [CONTACT_881639].  
Upon  request by  [CONTACT_122830],  the investigational product will be transferred  to the following  address:  
DMID -Clinical  Agents  Repository  
Contract  Fisher  BioServices  
[ADDRESS_1232592]  
Germantown,  MD, [ZIP_CODE]  
Tel: (240)  477-1350  
Fax: (240) 477 -1360  
Email:  [EMAIL_16775]  
 
Study  product will be shipped to  the investigational sites  upon  request and approval by  [CONTACT_122830].  
6.1.2.  Formulation, Packaging,  and Labeling  
The vaginal  gel applicators  will be packaged  as a kit sufficient  for twice daily  administration  for 3 
consecutive days (six applicators).  Each vaginal  gel dispensing kit  will be individually  labeled  
with the  protocol number,  dosing  instructions, recommended  storage  conditions, the name [CONTACT_881685], the  kit number,  Investigational Use Statement  (“Caution:  New Drug  – 

DMID Protocol No. 12 -0021   Version  8.0 23May2017  
35  Limited  by [CONTACT_4496]  [[LOCATION_003]]  Law to Investigational  Use”) and  that the agent should  be kept out of 
reach  of children.  
[IP_ADDRESS].  5% Monolaurin  Vaginal Gel  
 
Monolaurin Vaginal Gel  is a clear  and colorless  non-sterile  glycol -based gel  for vaginal  
administration.  Monolaurin Vaginal Gel is  comprised of 5% monolaurin and the following  
excipi[INVESTIGATOR_840]:  
 
Active test article will be comprised  of 5% monol aurin prepared as  pre-filled vaginal  gel 
applicators  of identical likeness  to placebo.  The components  of the applicator are  biocompatible  
and latex -free. 
[IP_ADDRESS].  Vehicle  Placebo  Gel 
The Vehicle Placebo  Gel is a clear to opaque, colorless  to light gray,  non-sterile  glycol -based gel  
for vaginal administration  and contains  the following:  
 
 The Vehicle Placebo Gel contains  the same excipi[INVESTIGATOR_881592].  
The Vehicle Placebo Gel  will be comprised of the identical vehicle contained in the  active  test 
article  prepared  as pre-filled vaginal gel applicators  of identical likeness  to active test article.  The 
components  of the applicator  are biocompatible and latex -free. 
6.1.3.  Product Storage and  Stability  
Vaginal applicators  containing  active  test article  or placebo will be stored  at room  temperature  (15-
30°C.)  with transient spi[INVESTIGATOR_881593] 40°C permitted  if they last less than 24 hours.  
6.2. Dosage,  Preparation  and Administration of Study  
Intervention/Investigational Product  
Preparation  
No formal preparation is  required  for the  study  product.  The unmasked  Research  Pharmacist  or 
designated unmasked study personnel maintaining the study  product accountability  will select  the 
appropriate  kit based on  the randomization scheme  and will label  the kit with the subject’s  name,  
subject ID number,  treatment number, and  any other  hospi[INVESTIGATOR_881594].  
Administration  
Study personnel will provide both verbal and  written  instructions  for proper storage  and 
administration.  The first dose will be administered by  [CONTACT_881640].  The remaining  5 doses  will be administered twice daily  (morning and evening)  with at  least 
[ADDRESS_1232593] dose after  3 pm, she 
will be instructed to  administer the next dose the  following  morning.  

DMID Protocol No. 12 -0021   Version  8.0 23May2017  
36  Dose of  Study  Agents/Interventions  
Active test article will be composed  of 5 mL of 5% Monolaurin  Vaginal Gel  prepared  as pre-filled  
vaginal gel applicators  of identical likeness  to placebo.  Vehicle  Placebo  Gel will contain [ADDRESS_1232594] article.  
6.3. Modification of  Study  Intervention/Investigational  Product  for a 
Participant  
If a subject  is found  to have a positive  test for HIV, chlamydia or gonorrhea  or Grade  [ADDRESS_1232595] the  unused 
applicator,  and resume dosing at the  next recommended  scheduled dose.  
6.4. Accountability  Procedures  for the  Study  Intervention/Investigational 
Product(s)  
The unmasked Research  Pharmacist will be responsible  for maintaining  complete  records  and 
documentation of study  product receipt, accountability,  dispensation,  storage  conditions, and  final 
disposition of the study product. All study  products, whether  administered or not, must be  
documented  on the appropriate study  product  accountability  record  or dispensing  log. 
Study  personnel will document on  the CRF the time of the application  of the first study  dose.  The 
first dose applicator may  be discarded.  Subjects  will be instructed  to return  the kit (containing  
used and/or unused vaginal applicators) to  study  personnel at the clinic  for Visit 2.  The used kit 
and applicators  will be placed in a sealed plastic  bag for transport to  the study  site. Once  the study  
personnel  have verified the  test article accountability,  the kits and  used applicators may  be 
discarded in an  appropriate  medical waste container.  
Upon completion  or termination of the study  and after the  final monitoring visit,  any remaining  
unused study  product will either  be returned  or destroyed appropriately  at the clinical site as  per 
Sponsor requirements  and instructions.  
6.5. Assessment  of Subject  Compliance  with Study  
Intervention/Investigational Product  
Study personnel will count the number of used/unused applicators  contained in each  returned  
subject kit and  record  this information in the  test article accountability  section of the subject’s  
CRF.  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
37   
6.6. Concomitant  Medications/Treatments  
Administration  of any medications, therapi[INVESTIGATOR_014],  or vaccines  will be documented in the  subject’s  
source documentation  and reported  on the subject’s  data acquisition  screen.  Concomitant  
medications  will include all medications, vitamins, and supplements  taken  within the 30  days 
before  enrollment  and through  Visit  3 (Day  28) or  early  termination,  whichever  occurs  first. 
Each subject will be instructed  to not use any  systemic, vaginal,  or perineal antibiotic, antifungal,  
immunosuppressant, or  anti-inflammatory  medication except  oral nonsteroidal anti -inflammatory  
medication during  study  participation  from study  Day 1 through  Visit  3 unless  absolutely  
necessary.  
Treatment with any  prescription  medication(s), over -the-counter preparations  and non- prescription  
medication(s)  intended  to treat the subject  for vaginosis  will be used only  if subject  is considered a  
clinical  failure.  In this case,  she will be referred  to her provider  for standard  of care treatment.  All 
treatment medications  must be documented on  the concomitant  medications  CRF.  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
38  7. STUDY  SCHEDULE  
7.1. Screening  and Enrollment  (Visit 1,  Day 1) 
Subjects  should be  scheduled  for visits  when  they are not menstruating  and instructed  to avoid  
inserting any  substance into  the genital  tract for 48 hours  before examination  at Visit  1, when  
possible.  Subjects  may present after having  clinical evaluation by  a non -study  clinician or  may 
present to  the research  clinic  directly.  
The following  procedures  will be performed:  
 Obtain  signed  informed  consent.  This should  be performed  prior to conducting  any of 
the assessments  listed  below.  
 Review  inclusion/exclusion  criteria  and collect  demographic  information.  
 Obtain  medical  history  and concomitant medications  (prescription  and over-the-counter  
drugs,  supplements,  and vitamins  taken  30 days prior to enrollment will  be reviewed  and 
documented).  
 Review  of contraceptive  methods and  recent menstrual  history.  
 Review  sexual  history.  
 Review  subject  report  of history  of previous  epi[INVESTIGATOR_881595],  the number  of 
epi[INVESTIGATOR_881596]  12 months  and treatments  given.  
 Assessment  of current  symptoms  of BV 
 Perform physical  exam.  
 Perform urine  pregnancy  test for female  subject  of childbearing  potential  prior to pelvic  
exam.   Must  be negative  prior to receipt  of study  drug.  
 Gynecologic  exam  for evaluation  of the cervix,  vagina,  and vulva:  
 Assessment for genital  tract infections  and lesions.   If evidence  of active  lesions  
consistent with  herpes  simplex  virus  infection  or other sexually  transmitted  
infection  (e.g.,  syphilis), subject  will be excluded  and may be referred  to her 
provider for further management.  
 Document  vaginal  discharge  (quantity, color, odor, and  consistency).  
 Document objective  signs  of inflammation  (edema,  erythema, excoriation).  
Inspection  and appearance  of the cervix,  vagina,  and vulva,  and document  
presence  or absence  of objective  signs  of inflammation  (edema, erythema,  
excoriation).  
 Document vaginal  secretion  pH testing  using  pH paper  4-6. 
 Saline  “wet  mount” for microscopic  examination  (performed  by [CONTACT_881641]):  
 Document the presence  of and percentage  of cells that are “clue  cells.”  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
39   
 If motile  flagellated  protozoa  are seen,  the subject  will be excluded  from  
participating  in the trial and referred  to her provider  to be treated  using  
established  standards.  
 KOH 10% “wet mount” for microscopic  examination  (performed  by [CONTACT_881642]):  
 Document presence  or absence  of fishy  odor on “whiff test”:  fishy  
(amine) odor released  by [CONTACT_277882] a drop of 10% KOH  to the 
vaginal  discharge.  
 Document presence  of pseudohyphae  or budding  spores.  
The subject will be enrolled based on  demonstration  of any three of the  four following  Amsel  
criteria:  
 Off-white  (milky  or gray), thin, homogenous  discharge  with minimal  or 
absent  pruritus or inflammation  of the vulva  or vagina.  
 ≥20% “Clue” cells  of total epi[INVESTIGATOR_881597].  
 Vaginal  secretion  pH >4.5.  
 Positive  “whiff  test”.  
***If the  subject  does not meet clinical  criteria  (based on Amsel  criteria)  for BV, she will not 
have  further vaginal  sampling performed and will not proceed  to randomization  and will not 
receive study  drug.  
If subject demonstrates  evidence  of BV:  
For those subjects  who have evidence of  BV based on  the above  criteria  and continue  to meet  
inclusion/exclusion criteria,  samples  will be collected in the  following  order:  
 Vaginal  swabs for the following:  
 Gram stain  of vaginal  smear (local  laboratory  preparation  and shipment  to the 
University  of Iowa  Clinical  Pathology  Laboratory).  
 Culture  or molecular testing for the following  will be taken:  
 OSOM®  rapid  Trichomonas  testing. OSOM  testing  is required  if the 
wet prep shows  no evidence  of motile  flagellated  protozoa.   If the wet 
prep was positive  for motile  protozoa,  then the diagnosis  of trichomonas  
has already  been confirmed  and OSOM  testing  is not required.   If 
positive  for Trichomonas, the subject will be excluded  from  
participating  in the trial and referred  to her provider  to be treated  using  
established  standards.  
 Bacteria  and Candida  species  (to be sent to the Central  Laboratory).  
 Chlamydia  trachomatis - testing  should  be performed  as per local  standards 
(to be sent to the Local  Clinical  Pathology  Laboratory).  If study  subject  
has had Chlamydia  trachomatis  testing  performed  within  the past [ADDRESS_1232596]  will be contact[CONTACT_881643].  
 Neisseria  gonorrhoeae - testing  should  be performed  as per local  
standards (to  be sent to the Local  Clinical  Pathology  Laboratory). If 
study  subject  has had Neisseria  gonorrhoeae  testing  performed  within  
the past [ADDRESS_1232597]  will 
be contact[CONTACT_881644].  
 Future  Use: If the subject  consents  to future  use, one Copan  ESwab  in liquid  
amies  will be collected  for future  use (to be transported  on cold packs  or ice  to 
the research  laboratory).  
 Obtain  approximately  [ADDRESS_1232598] can be used for screening.  
 Once all samples  have been obtained, the subject  will be enrolled  in IDES  and randomly  
assigned  to a treatment group.  
 Subjects  will be counseled  on proper administration  and storage  of the vaginal  gel. 
 Subjects  will self-administer  the first dose  of the investigational  vaginal  gel or 
vehicle  placebo  gel with observation  by [CONTACT_881645]. 
 Subjects  will receive  5 further  doses  (vaginal  applicators  with instructions) for self- 
administration  twice -daily  (morning  and evening)  with at least 8 hours  between  doses.  
 Subjects  will be instructed  to return  used applicators to the disposal  bag provided  in the 
kit to return  to the clinic  at Visit  2 (between  Study Days  8-15). 
 Review  for AEs/SAEs  
 Provide  counseling  to refrain  from penile -vaginal  or receptive  oral sexual  intercourse  or 
insertion  of any substance  (other than  study  product),  products, or objects between  Visit  
1 and Visit  2 and 48 hours  prior to Visit  3. 
 Provide  memory  aid and instruct  subject  on how to complete  the memory  aid for [ADDRESS_1232599] day  of therapy.  
 Counsel  subjects  on avoidance  of pregnancy (for all  female  subjects  of childbearing  
potential).  
*If a subject’s  laboratory  results show  a positive  gonorrhea,  chlamydia, HIV  test or  grade [ADDRESS_1232600], 
though  initial  contacts  may include other  forms  of communication  with follow -up discussions 
provide d by [CONTACT_540839].  
7.2. Visit  2 (Day  8 [Window: Days  8-15]) 
All subjects  will return  for Visit  2 on Day 8 (Window:  Days  8-15) at which  time the following  
assessments  will be performed.  
 Review  changes  in medical  history:  
 Review  symptoms  of BV since  Visit  1 and treatments  for BV other than  
investigational  drug.  
 Review  all concomitant  medications  since  Visit  1. 
 Review  for sexual  intercourse,  insertion  of intravaginal  substances,  or objects since  Visit  
1. 
 Review  for AEs and SAEs.  
 Review  Memory  Aid and collect  applicator  kit. 
 Perform targeted  general  physical  exam  based  on symptoms.  
 Perform  gynecologic  exam  of cervix,  vagina,  and vulva:  
 Assessment  of vaginal  discharge  (quantity,  color, odor, and  consistency).  
 Record  presence  or absence  of objective  signs  of inflammation  of cervix,  vagina  and 
vulva  (edema, erythema, excoriation)  and presence  or absence  of lesions.  
 Collect  vaginal  secretions  for pH testing  using  pH paper 4 -6. 
 Perform KOH 10% wet mount  on vaginal  (must  be performed  by a licensed  clinician  or 
trained  laboratory  personnel)  and record  “whiff  test”:  fishy  (amine)  odor released  by [CONTACT_881646] a drop of 10% KOH  to the vaginal  discharge.  
 Evaluate  for pseudohyphae  or budding  spores  (must  be performed  by a licensed  
clinician  or trained  laboratory  personnel).  
 Perform saline  wet mount  (must  be performed  by a licensed  clinician  or trained  
laboratory  personnel).  
 Evaluate  and record  presence  and percent  of ‘Clue’  cells in vaginal  secretions.  
 Record  for presence  of flagellated  protozoa (if positive,  refer to provider  for 
further therapy).  
 Collect  vaginal  swabs  for: 
 Gram stain  of vaginal  smear.  
 Swabs  for culture  of Gardnerella  spp.,  Mobilluncus  spp.,  Lactobacilli  
spp., Candida  spp. 
 Future  Use: If the subject  consents  to future  use, one Copan  ESwab  in liquid  
amies  will be collected  for future  use (to be transported  on cold packs  or ice  to 
the research  laboratory).  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
42   Obtain  approximately 10  cc of blood  for: 
 WBC  count,  hemoglobin, platelet,  neutrophil  count.  
 Creatinine,  ALT,  AST, total  bilirubin,  random  glucose.  
 Counsel  subjects  to refrain  from  penile -vaginal  or receptive  oral sexual  intercourse or  
insertion  of any substance,  products, or objects  into vagina  for 48 hours  prior  to Visit  3. 
 Counsel  subjects  on avoidance  of pregnancy (for all  female  subjects  of childbearing  
potential).  
 Subjects  will be counseled  to come  in for an unscheduled  visit if their vaginitis  symptoms  
recur/worsen  between  Visit  2 and 3. 
 Document  Investigator  assessment  of clinical  cure.  
If the signs  and symptoms  of BV fail to  resolve and further treatment  is required (in  the 
Investigator’s  opi[INVESTIGATOR_1649]), the subject will be referred  to her provider  for standard  treatment.  Therapy 
will be recorded  on the appropriate  source  document  and electronic  CRF (eCRF)  pages  and the 
subject  will be followed through Visit  3 for safety.  At Visit  3, these subjects  will be classified as  a 
clinical  failure.  
7.3. Visit  3, Final  Study  Visit  (Day  28 [Window: Days  22-31]) 
All subjects  will return  for Visit  3 on Day 28 (Window:  Days  22-31) at which  time the following  
assessments  will be performed:  
 Review  changes  in medical  history.  
 Review  all concomitant  medications  since  Visit  2. 
 Review  of BV symptoms and  treatments  for BV other than  investigational  drug.  
 Review  history  of sexual  intercourse, insertion  of intravaginal  substances  or objects  
within  the past 48 hours.  
 Review  Memory  aid if solicited  events  continued  at last visit  and collect applicator kit,  
if not done  at Visit  2. 
 Review  AEs/SAEs:   If AEs or SAEs  continue  at Visit  3, the study  team will  follow  until 
resolution  or stabilization  of the event.   Laboratory  abnormalities  that were stable  at Visit  
2 (i.e., were  abnormal  at Visit  1 prior  to receipt  of study  drug and continued  to be 
abnormal  but no worse  at Visit  2) do not need to be repeated  and are considered  
stabilized.   Laboratory  abnormalities that occurred  between  Visit  [ADDRESS_1232601] has stabilized  or resolved.  
 Perform targeted  general  physical  exam  based  on symptoms.  
 Gynecologic  exam  of cervix,  vagina,  and vulva:  
 Assessment  of vaginal  discharge  (quantity,  color, odor, and  consistency)  
 Assess  cervix,  vagina,  and vulva  for presence  or absence  of objective  signs  of 
inflammation  (edema,  erythema,  excoriation)  and/or  genital  lesions.  
 Collect  vaginal  secretions  for pH testing  using  pH paper 4 -6. 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
43   Perform KOH 10% wet mount on  vaginal  secretions  (performed  by [CONTACT_881647])  
 Record  “whiff test”: fishy  (amine) odor released  by [CONTACT_277882] a drop of 10% 
KOH  to the vaginal  discharge.  
 Evaluate  for pseudohyphae  or budding  spores  (performed  by a licensed  clinician  or 
trained  laboratory  personnel).  
 Perform saline  wet mount  (performed  by a licensed  clinician  or trained  laboratory  
personnel).  
 Evaluate  and record  presence  and percent  of “clue  cells”  in vaginal  secretions.  
 Record  for presence  of flagellated  protozoa  (if positive,  refer to provider  for further  
therapy).  
 Collect  vaginal  swabs for: 
 Gram stain  of vaginal  smear  
 Swabs  for culture  of Gardnerella  spp., Mobilluncus  spp., Lactobacilli  spp., and  
Candida  spp. 
 Future  Use: If the subject  consents  to future  use, one Copan  ESwab  in liquid  amies  will 
be collected  for future  use (to be transported  on cold packs  or ice to the research  
laboratory).   Document  Investigator  assessment  of clinical  cure.  
7.4. Early  Termination  Visit  
For subjects  who are withdrawn  from the study  early,  follow -up assessments  will be completed  
according to  the protocol  schedule, if possible,  including  review  of concomitant medications,  
history  of sexual intercourse, insertion of intravaginal substances  or objects  and BV  symptoms,  
gynecological exam, targeted physical exam  if indicated based  on symptoms, review  of clinical  
cure, blood  for WBC  count, hemoglobin, platelet, neutrophil count,  creatinine,  AST, ALT, total  
bilirubin,  random  glucose), vaginal sampling  (wet mount,  KOH preparation, and vaginal swabs  for 
Gram stain,  culture  of Gardnerella, Mobiluncus,  Lactobacillus  and Candida  spp.), return  of 
applicator kit (if applicable)  and reason  for termination or withdrawal.   If subject declines  to return  
for an in -person  visit, the  study  personnel  will seek  permission  to contact [CONTACT_881648]  
22-[ADDRESS_1232602] signs  and symptoms  of BV or other  genital infections, she will be referred  to her provider  for 
further management.  
7.5. Unscheduled Visit  
Unscheduled visits  may occur  at any time during the study.  The procedures  below  are to  be 
performed  at any unscheduled visit.  See the MOP for instructions  for documentation  and data 
reporting.  
 Obtain  interim  medical  history and  solicit  information  on vaginal  symptoms.  
 Perform a targeted  physical  exam  if indicated  based  on symptoms.  
 Perform  gynecological  exam  and collect appropriate  samples  (e.g.,  appropriate  clinical  
samples  for genital  infectious  pathogens).  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
44   Review  concomitant medications.  
 Review  of memory  aid, if applicable.  
 Review  of AEs/SAEs,  if applicable . 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
45   
8. STUDY  PROCEDURES/EVALUATIO NS 
8.1. Clinical  Evaluations  
Medical History:  Will be obtained by [CONTACT_881649].   Subjects  
will be queried  regarding a history  of significant medical disorders  of the head,  eyes, ears,  nose,  
throat, mouth, cardiovascular  system, lungs, gastrointestinal  tract, liver,  pancreas,  kidney,  nervous  
system,  blood, lymph  glands,  endocrine  system, musculoskeletal  system, skin, and  
genital/reproductive tract.  A history  of any allergies,  cancer,  immunodeficiency,  psychiatric  
illness,  substance  abuse,  and autoimmune  disease will be solicited.  
Concomitant Medications:  All current medications  and medications  taken  in the 30  days before  
enrollment (prescription  and over -the-counter drugs,  supplements  and vitamins)  will be included  
through  Visit  3 (Day  28) after enrollment.  Assessment of eligibility  also will include a review  of 
prohibited  medications  (per the exclusion criteria).  
Physical Examination:  This examination will be conducted at Visit 1  and will assess  general  
appearance  the following  areas/symptoms:  skin,  inguinal lymph nodes,  head,  eyes, ears,  nose,  
throat, neck, respi[INVESTIGATOR_696], cardiovascular,  abdomen,  extremities,  musculoskeletal,  and neurological.  
Gynecological Examination:  This examination will be conducted at each visit and will assess  for 
presence of discharge,  appearance of the cervix,  vulva,  and vaginal mucosa,  and presence of 
specific  lesions.  Bimanual  exam  is not required,  but may  be performed  at the  discretion of the 
licensed clinician.  
Targeted  Physical Examination:  This may be conducted at any study  visit based on interim  
medical history.  
Solicited Events  Assessments:  Study  personnel  will take a  brief history  of subjects  for assessment  
of AEs.  This will include genital signs  and symptoms  of odor, pain, tenderness,  discharge, 
swelling, itching,  and dryness.  
8.2. Laboratory  Evaluations  
8.2.1.  Clinical  Laboratory  Evaluations  
Clinical laboratory  evaluations  will be performed  by [CONTACT_881650].  
Specific  tests to be performed  are described below:  
 HIV testing  will be performed  as per local  standards  (performed  at Visit  1 only).   It 
is recommended  that an antibody  or antibody/antigen  test be used for screening.  If 
antibody  or antibody/antigen  testing  results  in an indeterminate  test, HIV PCR may 
be used to further evaluate  the HIV  status  of the subject.  
 Hematology  includes:  WBC count, hemoglobin,  platelet,  neutrophil  count.  
 Clinical  chemistry  includes:   creatinine,  AST (SGOT),  ALT  (SGPT),  and total 
bilirubin,  and glucose  (random).  
 Urine  Pregnancy  test: Urine  pregnancy  test in females  of childbearing  potential  will 
DMID Protocol No. [ADDRESS_1232603].  
 Sexually  transmitted  infection  testing:  Testing  for Chlamydia  trachomatis  and 
Neisseria  gonorrhoeae . Samples  will be obtained  and processed  as per local  clinic  
guidelines  and will be sent to the site Clinical  Pathology  Laboratory.   Either  culture  or 
molecular testing  for Neisseria  gonorrhoeae  and chlamydia  is acceptable.  
Trichomonas  testing  using  wet preps  may be performed  in the clinic  as per local  
clinic  guidelines.  The OSOM® rapid  Trichomonas  testing  will be performed  on all 
subjects  who do not have Trichomonas  identified  on wet prep at screening.  
One or more  of the laboratory  parameters  may be repeated at any time during  the study  as 
determined by  [CONTACT_737], if indicated  by [CONTACT_1149]. Grade  3 abnormal laboratory values  should 
be repeated  within 10 days if possible and  followed up as  clinically  relevant.  
8.2.2.  Special  Assays  or Procedures  
Vaginal  Swabs  (Please  refer to MOP  for details  on vaginal swab  collection)  
The study  coordinator or  investigator will label the  tubes  with a unique  identification number  and 
store  the vaginal swabs  inside the  supplied transport tubes  in an  insulated  cooler  with cold packs  or 
placed in  the refrigerator (2 -8°C) within  1 hour of collection.  The swabs  will be packaged  in 
accordance  with the  federal shippi[INVESTIGATOR_881598]. A  reconciliation 
system will be used to  facilitate  tracking of vaginal swab specimens. For    subjects  enrolled  at the  
Cincinnati  Children’s  Hospi[INVESTIGATOR_881599]  [ADDRESS_1232604] been labeled with  global trace  bar codes.  
Gram  stain Assay  (University  of Iowa)  
Slides  will be fixed using  the SOP  for using CytoPrep  fixation  (see the MOP)  at the  local site  from  
vaginal swabs  collected  from  every  subject  at Visits  1, 2 and  3 for central scoring.  The fixed slide 
will be sent  to the University  of Iowa VTEU team where  they will be transported  to the University  
of Iowa Clinical Pathology  Laboratory  for staining and analysis.  The smear will be evaluated for 
bacterial morphotypes  and interpreted in accordance with Nugent's  criteria  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
47   
(relative populations  of the morphotypes  Lactobacillus,  Gardnerella,  Bacteroides,  
Peptostreptococcus , and  Mobiluncus  spp. [11]) using  the standardized  0-10 point  scoring  system to 
interpret the  Gram stain  results  as follows:  
 0-3 classified  as normal/no  BV detected  
 4-6 classified  as intermediate  
 7-10 indicative  of BV 
 
Each stained  slide will be read by [CONTACT_881651]’s  
results.   Discordant results (results  that differ in  the absolute Nugent score)  will be re-reviewed  by 
[CONTACT_881652] a consensus.   If a consensus cannot be reached, the slide will be 
reviewed  by a third  observer  to resolve  the discrepancy.  A single Nugent score val ue will be 
recorded.  
The same  Gram  stained  slides  used to assess  the presence  of bacterial  morphotypes  will also be 
evaluated  for the presence  of yeast  by [CONTACT_881653] 100x  objective.   A categorical  score  will be 
assigned  to each specimen  slide,  after the reader  viewed  and examined  the entire  area of each 
stained  slide to determine  the presence  or absence  of yeast  cells showing  blastoconidia  (cell buds).  
8.2.3.  Specimen Preparation, Handling, and  Shippi[INVESTIGATOR_881600], handling,  storage, and shippi[INVESTIGATOR_881601].  
[IP_ADDRESS].  Instructions  for Specimen  Preparation, Handling,  and Storage  
After collection, study  required  vaginal swab  tubes  will be placed at 2 -8°C within 1 hour of 
collection and stored  at 2-8°C until shipped.  If subjects  have consented  to future  use, the  future  
use vaginal swabs  will be transported on  cold packs  or ice to the research laboratory  where  they 
will be vortexed for five  minutes  and then aliquoted into  three  cryovials  that will then be  frozen at  
-70 C or colder.  
[IP_ADDRESS].  Specimen Shipment  
Prior to  transport,  vaginal swab  tubes  containing  specimens  (which have been stored at 2-8°C) will 
be placed in a small  plastic  bag with a handful  of cotton balls, and  then placed in a  Styrofoam™  
container and cardboard box  with a  disposable  ice pack.  They  will be shipped to  the University  of 
Iowa by  [CONTACT_453482],  by [CONTACT_881654]  a drop box  or calling for  pi[INVESTIGATOR_881602].   
Specimens  will be shipped daily  Monday through  Thursday.  
For those who have consented  to future use, the  future use  specimens  (cryovials  containing  aliquots  
of the liquid amies  solution obtained  from the vaginal swabs), will be sent on  dry ice to the Fisher 
repository.  
“All infectious  specimens  will be transported using packaging mandated  in the Code of Feder al 
Regulations  (49 CFR  Part 173: Shippers,  General Requirements  for Shipments  and Packaging  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
48   
and under the  US Department of Transportation - Pi[INVESTIGATOR_881603]  (PHMSA)   and according to individual carrier  guidelines,  as applicable.”  
. 
DMID Protocol No. [ADDRESS_1232605]  immediately  (§ 312.64(b)).  Safety  will be assessed by  [CONTACT_881655] -solicited AEs  and SAEs.  A DSMB  will be convened by  [CONTACT_881656].  
Sponsors  are specifically  required  to notify  all participating  investigators  and FDA in a written  
IND safety  report of any AE associated with  the use of the drug that is  both serious  and 
unexpected,  and any finding from  tests in laboratory  animals  that suggests  a significant risk  for 
human subjects  (§ 312.32(c)(1)(i)(A),(B)).  More generally,  sponsors  are required  to keep each 
participating  investigator  informed  of new observations  discovered by  [CONTACT_881657] r 
on the  drug particularly  with respect to AEs and  safe use  (§ 312.55(b)).  
Also,  Investigators  are required  to report promptly  to the IRB all unanticipated problems  involving  
risks to human  subjects  or others  including AEs  that should be  considered  unanticipated problems  
(§§ 56.108(b)(1),  312.53(c)(1)(vii),  and 312.66).  
9.2. Methods  and Timing  for Assessing,  Recording,  and Analyzing  Safety  
Parameters  
9.2.1.  Adverse  Events  
AE monitoring and  reporting  is a routine part of every  clinical trial.  All clinical site staff and the 
Sponsor’s  employees  share in  the responsibility  for reporting AEs.  All clinical site staff  and the 
Sponsor’s  employees  who learn about  or are notified  of a SAE  must  collect and promptly report  
(24 hours) data  according to  the regulations.  Failure  to report  AEs according to  the timeframes  and 
definitions  as outlined in the  regulations  can result  in regulatory  actions.  
Adverse  Event:  ICH E6  defines  an AE as  any untoward  medical occurrence in a subject  or 
clinical investigation subject admini stered a pharmaceutical product regardless  of its causal 
relationship to  the study  treatment.  An AE can  therefore be  any unfavorable  and unintended sign  
(including  an abnormal laboratory  finding), symptom, or disease  temporally  associated with the  use 
of medicinal (investigational)  product.  The occurrence of an AE may come  to the attention of 
study  personnel during  study  visits and interviews  of a study  recipi[INVESTIGATOR_881604],  
or upon  review  by a study  monitor.  
All AEs  including  local and systemic  reactions  not meeting the  criteria  for “serious  adverse events”  
should  be captured on  the appropriate CRF.  Information to  be collected  includes  event  description, 
time of onset,  clinician’s  assessment of severity,  relationship  to study  product (assessed only  by 
[CONTACT_881658] a  diagnosis, which  would include MD, PA, Nurse  
Practitioner, DO), and  time of resolution/stabilization of  the event.  All AEs  occurring  while  on 
study  must be  documented  appropriately  regardle ss of relationship.  All AEs  will be followed to  
adequate  resolution  or are considered  stable.  
DMID Protocol No. [ADDRESS_1232606].  
Severity  of Event:  All AEs will be assessed  by [CONTACT_19811]  a protocol defined  grading 
system.  For events  not included in  the protocol defined  grading system, the  following guidelines  
will be used  to quantify  intensity.  
 Mild :  events  require  minimal  or no  treatment and  do not interfere  with the subject’s  
daily  activities.  
 Moderate : events  result in  a low level of inconvenience  or concern  with the 
therapeutic  measures.  Moderate  events  may cause  some  interference  with 
functioning.  
 Severe :  events  interrupt a subject’s  usual  daily  activity  and may require  systemic  
drug therapy  or other treatment.   Severe  events  are usually  incapacitating.  
Changes  in the  severity  of an AE should be  documented  to allow  an assessment  of the duration of 
the event  at each level  of intensity.  AEs characterized as  intermittent require  documentation of 
onset and duration of each epi[INVESTIGATOR_1865].  
Relationship  to Study Products:  The clinician’s  assessment  of an AE's  relationship  to test article 
(study  drug)  is part of the documentation process, but it  is not a  factor in  determining what  is or is 
not reported in  the study.  If there is  any doubt  as to whether  a clinical observation is  an AE, the 
event  should  be reported.  All AEs  must  have their relationship  to study  product  assessed  using the  
terms:  related  or not related.  In a clinical trial,  the study  product must  always  be suspect.  To help 
assess,  the following  guidelines  are used.  
 Related  – There  is a reasonable  possibility  that the  study  product caused  the AE. 
Reasonable  possibility  means  that there  is evidence  to suggest  a causal  
relationship  between  the study  product  and the AE. 
 Not Related  – There  is not a reasonable  possibility  that the administration  of the 
study  product  caused  the event.  
9.2.2.  Solicited  Events  
Solicited events  assessments  will be captured on a memory  aid starting  on Day 1, the  first day of 
therapy  and continuing  for [ADDRESS_1232607]  the presence  and intensity  of vulvo -vaginal solicited  events  on the memory  
aid. 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
51  Table  2: Solicited events & grading  
 Grade 1  Mild  Grade 2  Moderate  Grade 3  Severe  
Vaginal odor  Mild unpleasant  odor Moderate  unpleasant  odor Severe,  unpleasant  odor  
Vaginal pain  Pain causing  no or  minimal  
interference with  usual social  
and functional  activities  Pain causing greater  than 
minimal  interference with  
usual social  and functional  
activities  or the need  for non - 
narcotic medication  Pain causing  inability  to 
perform  usual social  and 
functional  activities  or the 
need  for narcotic medication  
Vaginal  tenderness  Mild tenderness  Moderate  tenderness  Severe tenderness  
Vulvar/vaginal itching  Itching  causing  no 
interference with  usual social  
and functional  activities  Itching  causing  interference 
with usual social  and 
functional  activities  Itching  causing  inability  to 
perform  usual social  and 
functional  activities  
Vaginal dryness  Dryness  not interfering with  
sexual  function,  social,  and 
functional  activities  Dryness causing  greater than  
minimal interference  with 
usual sexual,  social  and 
functional  activities  NA 
Vaginal discharge  by [CONTACT_3445]’s 
report  Mild increase  in participant’s 
usual  amount  of discharge,  
regardless  of color  or 
quantity; no  sanitary 
protection  required  Moderate to profuse  increase  in 
discharge requiring  pad use or 
other  hygienic  intervention  NA 
Vulvar  inflammation  
(Redness/Swelling)  Mild  swelling,  or redness; no  
interference with  usual, 
social and  functional  
activities  Moderate swelling,  or redness;  
interference with  usual, social 
and functional  activities  Severe swelling or  redness, or  
presence of mucosal  
ulceration;  inability  to 
perform  usual, social and  
functional  activities  
 
Any symptoms  still present  on Day [ADDRESS_1232608]  any medications  taken  and any  
emergency  room  or physician visits  (other than  routine  check -ups).  
Severity  of solicited events  symptoms  are graded  according to  the table above.   For symptoms  not 
specifically  mentioned will be graded using the  following  scale:  
 Grade  1:  Mild  (does  not interfere  with activity)  
 Grade  2:  Moderate  (interferes  with activity)  
 Grade  3:  Severe  (prevents  daily  activity)  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
52  9.2.3.  Serious  Adverse  Events  
An adverse event  or suspected adverse  reaction  is considered  “serious”  if, in the  view  of either  the 
investigator or sponsor, it results  in any  of the following  outcomes:  
 Death,  
 A life -threatening  AE*,  
 Inpatient hospi[INVESTIGATOR_116409],  
 A persistent  or significant  incapacity  or substantial disruption of the ability  to conduct  
normal  life functions,  or 
 A congenital anomaly/birth defect.  
 Important medical events  that may  not result  in death, be life -threatening,  or require  
hospi[INVESTIGATOR_881605],  based upon  appropriate  medical  
judgment, they  may jeopardize  the subject and  may require  medical or surgical 
intervention to  prevent one of the outcomes  listed in  this definition.  Examples  of such 
medical events  include allergic  bronchospasm  requiring intensive treatment in an 
emergency  room  or at home, blood dysc rasias  or convulsions  that do not result  in 
inpatient hospi[INVESTIGATOR_059],  or the  development  of drug dependency  or drug abuse.  
*Life -threatening  AE.  An AE is  considered  “life-threatening” if, in  the view  of either the  
investigator or sponsor, its  occurrence places  the subject  at immediate  risk of death.  It does not 
include an AE, had it  occurred in a  more  severe  form, might have caused  death.  
All SAEs  will be: 
 Reviewed  and evaluated by  a study  clinician  
 Recorded  on the appropriate Adverse Event  CRF 
 Followed  through  resolution by  a study  clinician  
 A study  clinician will determine whether the  SAE is considered  related  to study  
treatment.  
9.2.4.  Procedures  to be  Followed in the  Event of Abnormal Laboratory Test  Values  or 
Abnormal Clinical  Findings  
Collection of specifi c safety  laboratory  data is outlined  in the study  visit schedule.  Toxicity  tables  
are based  on the FDA toxicity  tables  developed  for normal healthy  adult  volunteers.  
Laboratory  values  that are abnormal based  on the toxicity  tables  will be reported  on the appropriate  
CRF.  
In the event  a subject  experiences  an AE or vulvar  or vaginal  reaction  that is  still present  at the end 
of the subject’s  participation in the  study,  the subject must be  followed  until resolution of the event  
or until the  event  or abnormality  stabilizes  to the  investigator's  and/or  sponsor's  satisfaction.  
Follow -up procedures,  evaluations,  and outcomes  will be recorded on  the subject's  CRFs.  
DMID Protocol No. [ADDRESS_1232609], date  of resolution of the event, seriou sness,  and outcome.  The 
intensity  of non-serious  AEs will be assessed by  a licensed study  clinician (i.e., medical doctor,  
nurse, nurse  practitioner, physician’s  assistant).  The causality  of non-serious  AEs will be assessed 
by a licensed  clinician  able to make  diagnoses listed on  the Form  FDA 1572.   All AEs  occurring 
during the AE  reporting  period of the study will be documented appropriately  regardless  of 
relationship.  All AEs  will be  followed to  adequate  resolution  or until considered  stable.  
Any medical condition that  is present  at the time of enrollment will be considered as  pre-existing  at 
Baseline and  will not  be reported  as an AE. If the severity  or frequency  of any pre-existing  
medical condition increases  during the  study  period, then it will be recorded as  an AE. 
AEs will be  followed until  resolution  even if this  extends  beyond the study -reporting  period.  
Resolution of an AE is  defined as  the return  to pretreatment  status  or stabilization of  the condition 
with the expectation that  it will remain chronic.  
[IP_ADDRESS].  Serious  Adverse  Events  
Information to  be collected includes  event  description,  date of onset,  investigator assessment  of 
severity,  investigator assessment  of relationship to study  product,  date of resolution of the event,  
seriousness, and  outcome.  The intensity  of SAEs  will be assessed by  a licensed study  physician.  
The causality  of SAEs  will be assessed by  a licensed  physician able to  make  diagnoses listed on  the 
Form FDA 1572.  
Serious  adverse events  will be recorded  on the appropriate  Adverse Event  CRF and  will be  
reported  to the site’s  Independent  Safety  Monitor.  Events  will be reviewed and  followed to  
resolution by  a study  physician.  SAEs  will be collected on  each subject until her  last study  visit.  
Any AE that meets  a protocol -defined serious  criterion  must  be submitted  immediately  
(within 24  hours  of site  awareness) on an  SAE  form to  the DMID  Pharmacovigilance  Group,  
at the following  address:  
DMID Pharmacovigilance  Group  
Clinical  Research Operations  and Management  Support (CROMS)  
[ADDRESS_1232610]. Suite  650 
Bethesda, MD [ZIP_CODE],  [LOCATION_003]  
SAE  Hot Line:  [PHONE_2618]  (US)  or [PHONE_2619]  (outside  US) 
SAE  FAX  Phone  Number:  [PHONE_2620]  (US) or  [PHONE_2621]  (outside  US) 
SAE  Email  Address:  [EMAIL_1393]  
 
 
DMID Protocol No. [ADDRESS_1232611]  be submitted  to the Statistical and  Data  Coordinating  Center  (SDCC),  
Emmes  Corporation, through  the IDES  system.  Other supporting documentation  of the event  may 
be requested  by [CONTACT_881659].  
The DMID  Medical  Monitor  and Clinical  Protocol  Manager  will be notified  of the SAE by  [CONTACT_413656].  The DMID Medical Monitor  will review  and assess  the SAE  for 
regulatory  reporting  and potential impact on  study subject safety  and protocol conduct.  
At any time after completion of the study,  if the investigator becomes  aware  of an SAE  that is  
suspected  to be related  to study  product, the investigator will report the  event  to the DMID  
Pharmacovigilance  Group.  
9.3.2.  Regulatory  Reporting  for Studies  Conducted Under DMID -Sponsored  IND 
Following  notification  from the investigator, DMID, the  IND sponsor, will report any  suspected  
adverse reaction that  is both serious  and unexpected.  DMID will report an AE as a suspected  
adverse reaction only  if there is  evidence to  suggest  a causal  relationship  between the drug and the 
AE.  DMID will notify  FDA and all participating investigators  (i.e., all investigators  to whom  the 
sponsor  is providing drug  under  its INDs  or under  any investigator’s  IND)  in an  IND safety  report  
of potential serious  risks  from clinical trials  or any other  source,  as soon as possible,  but in no case  
later than  15 calendar  days after the  sponsor  determines  that the information  qualifies  for reporting  
as specified in 21 CFR  Part 312.32.  DMID will also notify  FDA of any unexpected  fatal or life -
threatening  suspected  adverse  reaction as  soon as possible but in no  case later than 7  calendar  days 
after the sponsor’s  initial receipt  of the information.  Relevant  follow -up information to  an IND 
safety  report  will be submitted  as soon as  the information is  available.  Upon  request  from  FDA, 
DMID will submit to FDA  any additional data or information  that the  agency  deems  necessary,  as 
soon  as possible,  but in no  case later than [ADDRESS_1232612].  
All serious  events  designated as  “not related” to study product(s),  will be reported  to the FDA at  
least annually  in a summary  format.  
9.3.3.  Reporting of Pregnancy  
Pregnancies  occurring  in study  subjects  will be reported  in IDES. No  further treatment  will be 
administered  to pregnant subjects,  but all study -mandated blood  samples  will be obtained and  the 
subject  will continue in  follow -up for safety  events (see Section 7.6).  In addition,  pregnant subjects  
will no longer undergo  pelvic  exams  or swabs  collection.   Pregnancies  will be followed  to 
pregnancy  outcome  pending  the subject’s  permission.  
9.4. Type  and Duration of  Follow -up of Subjects  after  Adverse  Events  
AEs will be  followed until  resolved or subject is  considered stable.  
9.5. Halting Rules  
Study  enrollment and dosing  will be halted and an ad hoc  DSMB  review will be performed  if any 
of the following  occur  at any time during the  study:  
Study  Halting  Events:  
1. One or more  subject experiences  a treatment -related SAE.  
DMID Protocol No. [ADDRESS_1232613] experiences  vulvar  and/or vaginal ulceration,  abscess,  or necrosis  
associated with study  product  administration.  
3. Two or more  subjects  experience a  treatment -related severe  (Grade  3) unsolicited  adverse 
event.  
4. Three or more  subjects  who received at  least one treatment dose  experience the  same  severe  
(Grade  3) solicited AE as  evaluated by  a licensed clinician.  
5. Three or more  subjects  who received at  least one treatment dose  experience a severe  (Grade 
3) study  related  laboratory  abnormality  in the same laboratory  parameter.  
6. An overall pattern  of symptomatic, clinical,  or laboratory  events  that the DMID,  Medical  
Monitor,  or DSMB  consider  associated with study  product and  that may collectively  
represent  a serious  potential concern  for safety.  
9.6. Safety  Oversight  (ISM  plus DSMB)  
9.6.1.  Data  and Safety  Monitoring Board  
Because this  is a large Phase  II Randomized  Clinical Trial,  a DSMB  will be created  to review  this 
study.   The DSMB  will be composed  of three  to four members  and may include at  least one  
physician involved in research, one biostatistician and potentially  an expert  in the field of 
microbiology.  This committee  will be charged  with reviewing  the protocols  with respect to  ethical 
and safety  standards  and making recommendations  if necessary.  During the  studies,  the 
Committee will meet (either in person, via teleconference  or web -based meetings) at least  annually  
to review  safety  issues  and to monitor center performance in  execution of the protocol.  
Prior to each  meeting, a  formal,  detailed report will be generated  with emphasis  placed on  safety  
issues.  
A formal DSMB  review will occur  after [ADDRESS_1232614] completed  Visit  2. The DSMB  will either  recommend  continued  enrollment of the 
remaining subjects  or discontinuation of enrollment.  Though  the timing of the DSMB  review will 
be expedited,  enrollment may  continue while  awaiting the  DSMB  review.  In addition,  a 
computerized system  will be used  to acquire  any data regarding  halting criteria  throughout the  
study.  
Additionally,  a single  fully blinded interim  analysis  is planned  to reassess  the adequacy  of the 
sample size based on  subjects  meeting  eligibility  for the Modified  Intent -to-Treat (mITT)  cohort  
(see also  Section 11).  After  eighty  subjects  have been enrolled and  have available test results  for 
Nugent score,  HIV, chlamydia  and gonorrhea, the  fraction  of subjects  who are enrolled to  date who 
are eligible  for the  mITT  cohort will be estimated.  Based  on this calculation,  the enrollment target 
may be increased  from [ADDRESS_1232615] unmasking to  make determinations  
regarding  study  outcome.  
9.6.2.  Independent Safety  Monitor (ISM)  
Safety  oversight for this  study  will include an ISM in close proximity to each of the clinical  
research  sites. The  ISM will receive and evaluate  SAEs  blinded and provide  an independent  written 
summary  to the DMID  Clinical Project Manager  and DMID Medical Monitor. The  ISM may be 
asked  by [CONTACT_881660]  (i.e. significantly  increased  
frequency  of non-serious  adverse events).  
DMID Protocol No. [ADDRESS_1232616]  protection, study  procedures,  
laboratory  procedures,  study  intervention administration, and data  collection processes  are of high 
quality  and meet  sponsor, International Confere nce on  Harmonisation (ICH)/Good Clinical  
Practice  (GCP) guidelines  and applicable regulatory  requirements,  and that the  study  is conducted 
in accordance  with the protocol  and sponsor’s  standard  operating procedures.  The DMID or  its 
designee  will conduct site-monitoring visits  as specified in  the monitoring plan.  
Monitoring visits  will include,  but are not limited  to, review  of regulatory  files,  accountability  
records,  CRFs,  informed  consent  forms (ICFs), medical and laboratory  reports,  and protocol  
compliance.  Study  monitors  will meet with investigators  to discuss  any problems  and actions  to 
be taken  and document  visit findings  and discussions.  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
58  11. STATISTICAL  CONSIDERATIONS  
11.1. Introduction  
This is a Phase  2, double -blind,  randomized,  placebo -controlled, multi -center trial comparing 5%  
Monolaurin Vaginal Gel  to Vehicle Placebo Gel  as outpatient therapy.  A total of 120 eligible  
subjects  with BV will be enrolled.  Treatment  assignments  will be randomly  allocated in a 2:[ADDRESS_1232617]  will 
receive intravaginal  gel twice daily  for three successive  days for a total of 6 doses.  There  will be  3 
clinic  visits  over 31 days.  
11.2. Data  Analysis  Populations  
The Per-Protocol  (PP) efficacy  analysis  population includes  all randomized  subjects  who met all  
inclusion/exclusion criteria,  did not have any significant  protocol deviations, complied with the  
assigned  study  treatment, returned  to the study  site for the  Test of Cure  visit within the specified  
window  (Visit  [ADDRESS_1232618] day of treatment  [Window: Days  8-15]),  or 
discontinued  study  product  early  due to  lack of treatment  effect or received vaginosis  or systemic  
antimicrobial therapy  other th an study  drug during  the study.  Subjects  with Visit  [ADDRESS_1232619], a PAP result consistent with HSIL, AGUS, or CIN2 or greater, or a Visit 1 
Nugent  score  < [ADDRESS_1232620],  as 
assessed by  [CONTACT_171427]’s  count of used / unused applicators  in each returned  subject  kit. 
If a kit is not returned,  compliance will be assessed by [CONTACT_19578]’s  self-report on  the memory  aid.   
Significant protocol deviations  include sexual intercourse including  receptive oral  sex or insertion 
of substances  or objects  intravaginally  between Visit  1 and  Visit  2. 
The Modified Intent -to-Treat (mITT) efficacy  analysis  population includes  all randomized  subjects  
who met all inclusion/exclusion criteria  excluding  those who have a Nugent score  <[ADDRESS_1232621] of 5% Monolaurin  Vaginal Gel  to Vehicle Placebo Gel.  
The Evaluable  efficacy  analysis  population includes  all subjects  in the  mITT population who 
received study  treatment and  returned  for at least one post -baseline visit.  
The Intent -to-Treat (ITT) efficacy  analysis  population includes  all randomized  subjects.  
The safety  population includes  all randomized subjects  who received at  least one dose of study  
product.  
11.3. Study  Objectives  and Endpoints  
The primary  study  objectives  are to  compare 5% Monolaurin Vaginal Gel  with vehicle  placebo  gel 
(excipi[INVESTIGATOR_881586])  with respect to  1) safety  and tolerability,  and 2) efficacy  by [CONTACT_881661]  
2. The primary  safety  outcome  measures  are the number  of subjects  reporting  solicited  urogenital 
AEs following  the first dose  of the study product through Visit  2 (Days  8-15) and  the number of 
DMID Protocol No. [ADDRESS_1232622] 
through Visit 3  (Day 22-31). The  primary  efficacy  outcome  measure  is the proportion  of subjects  
with clinical cure in each  study  arm at Visit  2 (Days  8-15). 
A clinical cure is  defined  by [CONTACT_881662].  Normal  Amsel criteria  are defined as:  normal 
physiological vaginal discharge,  whiff test negative  for any amine “fishy” odor,  saline wet mount 
less than 20%  for clue cells,  and vaginal pH is  <=4.5.  
A clini cal failure  is defined by  a) one or more  abnormal  Amsel criteria, b) early  discontinuation of 
study  therapy  due to  lack of treatment effect, c) use of  any vaginosis  therapy  other than study  
product  during the  study, or d) in the investigators  opi[INVESTIGATOR_1649],  requires  additional treatment for 
vaginosis.  
Subjects  who do not  meet the criteria  for either the clinical cure or clinical  failure definitions  are 
not evaluable for clinical cure.  
A secondary  efficacy  outcome  measure is  the proportion of subjects  with therapeutic  cure in each 
study  arm at Visit  2 (Day  8-15) and  at Visit  3 (Day  22-31). Therapeutic  cure is defined  as both a  
clinical cure AND  a bacteriological cure  (Nugent  score 0-3).  Subjects  who were  clinical  failures, 
or have a Nugent  score  >[ADDRESS_1232623] a Nugent  score  result  are not evaluable for therapeutic  cure.  
Table  3: Bacterial Vaginosis:  Determination of Therapeutic Cure  
If the clinical  cure  outcome  is… and the  Nugent  (bacteriological)  
score result is…  then the overall  therapeutic cure  
outcome  is… 
Cure  0-3 Cure  
Cure  >3 Failure  
Cure  Not Evaluable  Not Evaluable  
Failure  0-3 Failure  
Failure  >3 Failure  
Failure  Not Evaluable  Failure  
Not Evaluable  0-3 Not Evaluable  
Not Evaluable  >[ADDRESS_1232624] will be used as  a sensitivity  analysis.  Non-evaluable  therapeutic  
cures  will be handled similarly.  
11.4. Study  Hypotheses  
There are  three  planned  formal tests  of hypotheses  which  compare 5% Monolaurin Vaginal  gel 
with Vehicle Placebo Gel  (excipi[INVESTIGATOR_881586]),  with respect to  the primary  safety  and efficacy  
outcomes.  The first hypothesis  test compares  the proportion of subjects  in each study  arm who 
experience solicited urogenital AEs  through Visit  2 (Day  8-15 study  window).  The second  
DMID Protocol No. [ADDRESS_1232625] through Visit 3  (Day  22-31). The third  
hypothesis  test compares  the proportion  of subjects  who achieve  clinical cure at Visit 2  (Day  8- 
15). The null hypothesis  for each comparison is  that there  is no difference  in proportions  between 
study  arms, with a  two-sided alternative which conside rs the possibility  of a difference  in either  
direction.  Each  test will be conducted using  a Fisher’s  exact test at the 5% two-sided  level of 
significance  level  without  adjustment  for multiplicity.  The two safety  hypotheses  will be tested  in 
the safety  data analysis  population.  The primary  efficacy  analysis  will be conducted  in the mITT 
efficacy  analysis  population, and  repeated as  a secondary  analysis  in the  PP efficacy  analysis  
population,  Evaluable efficacy  analysis  population and  Intent -to-Treat efficacy  analysis  
population.  
11.5. Sample  Size Considerations  
The statistical information  goal for the  study  is [ADDRESS_1232626] a Nugent  score  <[ADDRESS_1232627] 
120 subjects to a  maximum  of 150, if necessary  to reach  the informational goal of 90 eligible  
subjects.  
The table below  shows  the statistical power  conferred  by [CONTACT_881663] a two-sided level  5% 
Fisher’s  exact test comparing  binomial proportions,  under different  assumed  proportions.  
  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
61  Table  4: Power to compare binomial proportions using a two -sided level 0.05 Fisher’s 
Exact Test with a sample size of N = 90 (60 subjec ts in the 5% Monolaurin 
Vaginal Gel arm, 30 subjects in the Vehicle Placebo Gel arm) Conditions in 
which Power is ≥.80 are highlighted   
Vehicle  Placebo  Gel (N=30)   
5% Monolaurin  Vaginal Gel (N=60)  
  
.05  
.10  
.20  
.30  
.40  
.50  
.60  
.70  
.80  
.90  
.95 
 
.05  
.02  
.04  
.38  
.82  
.97  
>.99  
>.99  
>.99  
>.99  
>.99  
>.99 
 
.10  
.13  
.03  
.15  
.52  
.85  
.98  
>.99  
>.99  
>.99  
>.99  
>.99 
 
.20  
.53  
.22  
.03  
.12  
.42  
.78  
.96  
>.99  
>.99  
>.99  
>.99 
 
.30  
.86  
.61  
.15  
.03  
.12  
.41  
.76  
.95  
>.99  
>.99  
>.99 
 
.40  
.98  
.89  
.47  
.13  
.04  
.13  
.41  
.76  
.96  
>.99  
>.99 
 
.50  
>.99  
.98  
.79  
.42  
.13  
.04  
.13  
.42  
.79  
.98  
>.99 
 
.60  
>.99  
>.99  
.96  
.76  
.41  
.13  
.04  
.13  
.47  
.89  
.98 
 
.70  
>.99  
>.99  
>.99  
.95  
.76  
.41  
.12  
.03  
.15  
.61  
.86 
 
.80  
>.99  
>.99  
>.99  
>.99  
.96  
.78  
.42  
.12  
.03  
.22  
.53 
 
.90  
>.99  
>.99  
>.99  
>.99  
>.99  
.98  
.85  
.52  
.15  
.03  
.13 
 
.95  
>.99  
>.99  
>.99  
>.99  
>.99  
>.[ADDRESS_1232628],  the 95% confidence interval for  the 
estimated proportion  is (.00,.06) (Clopper -Pearson interval).  
In actuality,  the safety  analysis  cohort  will be larger than  the mITT cohort,  and the confidence  
interval will be more precise  than this. 
11.6. Planned Interim  Analyses  
The DSMB  will meet  and review  safety  data and  enrollment data  when  [ADDRESS_1232629] access  to the data shared in  fully 
blinded reports  issued to  the DSMB.  
11.7. Final  Analysis  Plan  
The primary  and secondary  analyses  are briefly  described in  this section.  Further  details  of the 
analyses  as well as  the analysis  plan for the exploratory  analyses  will be described in a  separate  
statistical analysis  plan document.  
11.7.1.  Safety  Analyses  
[IP_ADDRESS].  Overview  of Safety Analyses  
 
Solicited  Adverse Event  Data 
Descriptive techniques  will be used to  summarize  the solicited adverse  events  data.  Local and  
systemic  solicited events  will be tabulated,  with symptom type crossed by  [CONTACT_168767].  
Tables  will be prepared  for each treatment  arm, and for the combined safety  analysis  cohort.  The 
data in each  table will also be depi[INVESTIGATOR_881606] , as a bar -chart of symptom  incidence,  and 
provided as  listings  of events.   In the tables, figures  and listings, color -coding using  a heat chart 
(yellow,  orange, red)  will be used to  highlight  severity  (mild, moderate, severe).  
The solicited AE outcome  data consist of multiple symptoms  types,  with ordinal severity  grades,  
taken  repeatedly  over a 5-day reporting period  following first administration of study  product.  To 
facilitate analysis  and interpretation, the  data will be simplified in different ways  in different  
analyses.  For example,  individual  symptoms  will be used  to form the  composite endpoint “any  
local symptom”.  The ordinal severity  grades  will be dichotomized,  e.g., none  or mild versus  
moderate or severe.  The grade  will be summarized by  [CONTACT_881664] a single observation per subject.  
Unsolicited  Adverse Event  Data  
Unsolicited AEs  will be coded by  [CONTACT_61132]® for preferred  term and system  organ class. The  
proportion of subjects  and exact  95% confidence intervals  of AEs in aggregate, as  well as by 
[CONTACT_61132]® categories, will be computed.  The number  of SAEs  is likely  to be small in  this study  
and will be reported by  a detailed listing  showing  the type,  MedDRA® coding,  relevant  dates  
(treatment dosing  dates  and AE onset  and resolution dates), severity, relatedness, and  outcome  for 
each event.  
Clinical Safety  Laboratories  
Results  of safety  laboratories  assessed prior to and after administration  of study  product will be  
summarized by [CONTACT_881665].  Changes  in laboratory  parameters  pre- and post- 
DMID Protocol No. [ADDRESS_1232630]  
deviations  and 95% confidence intervals,  will be computed.  Additionally,  graded  results  will 
either  be analyzed  as a binary  variable (normal,  abnormal),  or a multinomial variable (Grade  0, 
Grade  1, Grade  2, Grade  3) using either  logistic  regression or ordinal logistic  regression  
respectively  to make  treatment group comparisons.  
[IP_ADDRESS].  Analys es of  Primary  and Secondary  Safety  Outcomes  
All safety  outcomes  will be assessed  in the safety  analysis  population of all randomized  subjects  
who received one or more doses  of study  product.  Outcomes  will be reported  overall and  by 
[CONTACT_2890]. 
 Primary  Safety  Outcome  – 
 Number  of subjects  reporting  solicited  urogenital  AEs following  the 
first dose of the study  product through  Visit  2 (Day  8-15) 
 Number  of subjects  reporting  serious  adverse  events  (SAEs) considered  
product -related  following  the first dose of the study  product through  Visit  
3 (Day  22-31) 
 Secondary  Safety  Outcomes  – 
 Number  of subjects  experiencing  non-laboratory  non-solicited  AEs following  the 
first dose  of the study  product  through  Visit  3 (Day  22-31) 
 Number  of subjects  experiencing  laboratory  AEs following  the first dose of 
the study  product through  Visit  2 (Day  8-15). 
 
Two tests  of hypotheses  will be conducted in  the safety  analysis  population.  Each  test will be 
conducted using  a Fisher’s  exact test at the 5% two-sided level of  significance level  without  
adjustment for multiplicity.  The point  estimate  for the  arm-specific  proportions  and difference in  
proportions  as well as corresponding two -sided level 95% confidence  intervals  will be reported.  As 
described  in Section  [IP_ADDRESS],  additional descriptive analyses  of solicited adverse event  data,  
unsolicited adverse event  data, and clinical safety  laboratory  values  will be  performed.  
11.7.2.  Efficacy  Analyses  
[IP_ADDRESS].  Overview  of Efficacy  Analyses  
[IP_ADDRESS].1.  Analyses of  Primary  and Secondary  Efficacy  Outcomes  
 Primary  Efficacy  Outcome – the proportion of subjects  with clinical cure  in each study  
arm at Visit  2 (Day  8-15). 
A test  of hypothesis  for the primary  efficacy  outcome will be conducted in  the mITT  efficacy  
analysis  population,  and repeated  as a secondary  analysis  in the PP efficacy  analysis  population,  
Evaluable  efficacy  analysis  population,  and Intent -to-Treat  efficacy  analysis  population.  Fisher’s  
exact test at the 5% two-sided level of significance level will be used  without  adjustment for 
multiplicity.  The point  estimates  for the  arm-specific  proportions  and difference  in proportions  as 
well as corresponding 95% confidence  intervals  will be reported.  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
64   
 Secondary  Efficacy  Outcomes  – 
 Proportion  of subjects  with therapeutic  cure in each study  arm at Visit  2 (Day  8- 
15) and at Visit  3 (Day  22-31). 
 Proportion  of subjects  with clinical  cure in each study  arm by [CONTACT_4838]  3 (Day  22-31) 
 Proportion  of subjects  with Nugent score  of 3 or less (negative  for BV) and 4-6 
(intermediate) in  each study arm at Visit 2 (Day  8-15) and  at Visit 3 (Day  22-31) 
The analyses  of the secondary efficacy  outcomes  will be conducted in  the mITT efficacy  analysis  
population  and repeated in  the PP  efficacy  analysis  population,  Evaluable  efficacy  analysis  
population and Intent -to-Treat  efficacy  analysis  population.  The point  estimates  for the  arm-
specific  proportions  and difference  in proportions  as well as corresponding  95% confidence  
intervals  will be reported.  
Additional descriptive a nalyses  of the primary and secondary efficacy  outcomes  will be  performed  
including tabular  and graphical displays  of the data, reporting  outcomes  overall and  separately  by 
[CONTACT_2890]. 
[IP_ADDRESS].2.  Analyses  of Exploratory  Efficacy  Outcomes  
 Proportion  of subjects  with clinical cure  in each  study  arm by [CONTACT_6496]  (first time  or 
recurrent infection)  by [CONTACT_4838]  2 (Day  8-15) and by [CONTACT_4838]  3 (Day  22-31). 
 Proportion  of subjects  with therapeutic  cure in each study  arm by  [CONTACT_6496] (first  time 
or recurrent  infection)  by [CONTACT_4838]  2 (Day  8-15) and by [CONTACT_4838]  3 (Day  22-31). 
 Mean  count  of Lactobacillus  spp., Gardnerella spp. , and Mobiluncus  spp., respectively,  
in each study arm at baseline,  at Visit  2 (Day  8-15) and at Visit  3 (Day  22-31). 
 Mean  fungal colony  count  in vaginal secretions  in each study  arm at baseline,  at Visit  2 
(Day  8-15) and at Visit  3 (Day  22-31). 
Analyses  of the exploratory  efficacy  outcome  measures  will be detailed in the  separate  statistical 
analysis  plan document.  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
65  12. SOURCE  DOCUMENTS  AND  ACCESS  TO SOURCE  
DATA/DOCUMENTS  
Each participating site  will maintain appropriate  medical and research  records  for this  trial, in 
compliance with ICH E6, Section 4.9, and  regulatory  and institutional requirements  for the  
protection of confidentiality  of subjects.  Each site  will permit  authorized representatives  of the 
DMID,  its designees, and appropriate  regulatory  agencies  to examine (and when  required by  
[CONTACT_61285], to copy)  clinical records  for the  purposes  of quality  assurance (QA) reviews,  
audits,  and evaluation of the study  safety  and progress.  These  representatives  will be permitted  
access  to all source data,  which  include,  but are  not limited  to, hospi[INVESTIGATOR_1097], clinical and  office  
charts, laboratory  notes, memoranda, subjects’  memory  aid or evaluation  checklists,  pharmacy  
dispensing records, recorded data  from automated  instruments, copi[INVESTIGATOR_881607], microfiches,  photographic  negatives, microfilm 
or magnetic  media, X -rays, Gram  stain  slides,  and subject  files and records  kept at the pharmacy, 
at the  laboratories,  and medico -technical departments  involved  in the clinical trial.  Data collection  
forms  will be derived  from the  eCRFs  and be  provided by  [CONTACT_80938].  The authority  to collect this 
information is  under  [ADDRESS_1232631]  or other source  documents  for 
monitoring.  Medical  history  and inclusion/exclusion evaluations  are by  [CONTACT_881666].  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
66  13. QUALITY  CONTROL  AND  QUALITY  ASSURANCE  
Following  a written DMID -accepted  site quality  management plan, the  investigational site  is 
responsible  for conducting routine QA  and quality  control  (QC)  activities  to internally  monitor  
study  progress  and protocol compliance.  The site PI [INVESTIGATOR_727799] -related  
sites, source  data/documents, and  reports  for the  purpose of monitoring and auditing by  [CONTACT_103], and inspection  by [CONTACT_58700].  The site PI [INVESTIGATOR_881608].  
DMID -designated clinical monitors  will verify  that the clinical trial is  conducted and data are  
generated,  documented  (recorded),  and reported  in compliance with the  protocol, ICH/GCP  
guidelines,  and the applicable regulatory  requirements.  Clinical monitoring reports  will be  
submitted  to DMID.  
The SDCC  will implement QC procedures  beginning with the data entry  system and  generate  data 
QC checks  that will be run  on the database.  Any missing  data or data anomalies  will be 
communicated  to the site(s)  for clarification and  resolution.  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
67  14. ETHICS/PROTECTION  OF HUMAN  SUBJECTS  
14.1. Ethical Standard  
The investigator  will ensure  that this  study  is conducted in  full conformity  with the  principles  set 
forth in  The Belmont  Report:  Ethical Principles  and Guidelines  for the  Protection of Human  
Subjects  of Research of the US National Commission  for the  Protection of Human Subjects  of 
Biomedical and Behavioral Research  (April 18, 1979)  and codified in 45  CFR Part 46 and/or the  
ICH E6; 62 Federal Regulations  [ZIP_CODE]  (1997).  The investigator’s  Institution will hold a current  
Federalwide  Assurance (FWA)  issued  by [CONTACT_881667] (OHRP)  for 
federally  funded  research . 
14.2. Institutional  Review  Board  
Prior to enrollment of subjects  into this trial, the approved  protocol  and the ICF will be reviewed  
and approved by  [CONTACT_881668].  The responsible official  for the  IRB will sign the  IRB letter  
of approval  of the protocol prior to  the start of this trial and a  copy  will be provided  to DMID.  
Notification of the IRB's  composition, or the  IRB’s FWA  number,  will be provided to DMID.  
Should amendments  to the protocol be  required, the amendments  will be written by  [CONTACT_881669].  
14.3. Informed Consent  Process  
All subjects  must sign an  ICF that complies  with the requirements  of both [ADDRESS_1232632]’s  receipt  of the investigational product.  This new information will be 
communicated by  [CONTACT_881670].  The informed  consent document will be updated  and subjects  will be re -
consented, if necessary.  
14.4. Exclusion of Women,  Minorities,  and Children  (Special  Populations)  
This study  will be inclusive of  all healthy  non-pregnant  women,  non-breastfeeding  who meet the  
inclusion/exclusion criteria, regardless  of religion, or  ethnic  background.  Only  individuals  who 
DMID Protocol No. [ADDRESS_1232633] by [CONTACT_3486], their staff, the  sponsor(s), an d their agents.  
This confidentiality  extends  to genetic  and biological sample  tests, in addition to  the clinical  
information  relating to  participating  subjects.  
The study  protocol, documentation,  data,  and all other information  generated will be held in strict  
confidence.  Documented  evidence that shows  that a potential investigator is  aware  of and agrees  
to the confidential nature  of the information related  to the study  must  be obtained  by [CONTACT_15276] a 
confidentiality  agreement.  No information concerning the  trial or the data will be released to  any 
unauthorized  third party  without  prior  written  approval of the sponsor.  
All information  provided  by [CONTACT_881671]  (other than a subject’s  medical records) will be kept confidential by  [CONTACT_468500].  This information  and data  will not  be used by [CONTACT_881672].  These restrictions  do not apply  to: (1) 
information  that becomes  publicly  available through no  fault of the investigator or  site staff; (2)  
information  that it  is necessary  to disclose in confidence  to an IRB solely  for the  evaluation of  the 
study; (3)  information  that it  is necessary  to disclose in order to  provide  appropriate  medical  care to 
a study  subject;  or (4) study  results  that may  be published as  described in Section 16.  If a written 
contract  for the conduct of the study  that includes  confidentiality  provisions  inconsistent  with this  
statement is  executed, that contract’s  confidentiality  provisions  shall apply  rather than  this 
statement.  
The study  monitor,  applicable  regulatory  authorities,  such as  the FDA, or  other authorized  
representatives  of the sponsor may  inspect all documents  and records  required to  be maintained by  
[CONTACT_16541]. This  includes,  but is not limited to, medical records  (office, clinic,  or 
hospi[INVESTIGATOR_307]) and pharmacy  records  for the subjects  in this trial. The participating  sites will permit  
access  to such  records.  
14.6. Study  Discontinuation  
If the study  is discontinued,  enrolled subjects  will continue to  be followed for  safety  assessments.   
Subjects  will be instructed  to discontinue use of study  product.  If signs  or symptoms  of BV or 
other  genital infections  persist either during the  study  or at the last visit, the  subject  will be referred  
to her provider for further  management.  
If the study  drug is discontinued prior to  completion of the 3-day course of therapy,  subjects  will 
continue to  be evaluated  for symptoms  of ongoing BV or other genital infections  and will be  
referred  for further therapy  if signs  and symptoms  persist.  
Subjects  will be compensated  for the  participation in this  study.  Compensation will be in  
accordance  with the local IRB’s  policies  and procedures, and subject  to IRB approval.  
DMID Protocol No. [ADDRESS_1232634].  Each  sample  will be encoded (labeled) only with a barcode 
and a unique  tracking  number to  protect  subject’s  confidentiality.  
There are no  benefits  to subjects  in the collection, stora ge, and  subsequent research  use of 
specimens.  Reports  about  future  research done  with a subject’s  samples  will NOT  be kept in their 
health  records.  Subjects  can decide  if they want  their samples  to be  used for future  research  or 
have their samples  destroyed at  the end of the study.  A subject’s  decision can  be changed  at any  
time prior to  the end  of the study  by [CONTACT_881673].  However,  if a 
subject consents  to future  use and some  of their blood  or swab  specimens  have already  been used  
for research  purposes, the  information  from that research  may still be used.  
14.8. Information Provided  to Subjects  at Study  Completion  
There is  increasing  discussion in the  research  community  in support  of disclosure of individual  
research  results.  Several  ethical principles  have been invoked, including respect for persons  who 
have the right to access  information about  their own health regardless  of the utility  of those  results,  
if they wish to do  so.  Surveys  suggest that many  research participants  value  and desire  the return 
of research  results.  Arguments  against  disclosure  include:  i) individual research  results  are often of 
experimental nature  and difficult  to translate  into useful  clinical applications;  
ii) some  results  have the potential to  provoke unnecessary  distress  and anxiety;  and iii)  
expectations  of disclosure may  set a false inducement  for participation.  
In this protocol, we intend to  provide each participant  with a lay  summary  of overall study  results.  
In addition, participants  may choose  to receive  their individual results  (e.g., their  treatment  
assignment or individual endpoint  data,  as appropriate)  and will be informed  about  any risks  and 
benefits  of disclosure.  Offering  participants  the option to  decline  and explaining  the clinical 
significance of individual  treatment is  intended  to minimize the  negligible  risks  associated with 
disclosure.  Interested  subjects  will be  asked  to provide  contact [CONTACT_881674].  Results  will be provided  in an  IRB-approved written  document after  the Clinical 
Study  Report has  been finalized.  
DMID Protocol No. [ADDRESS_1232635] enrolled in the  study.   All source documents  should  be 
completed in a  neat,  legible manner to  ensure  accurate  interpretation of data.  Permanent ink is 
required  to ensure  clarity  of reproduced  copi[INVESTIGATOR_014].  When  making  a change  or correction, the  original 
entry  should be  crossed out with a  single  line, and the change should be initialed and  dated.  Do 
not erase,  overwrite,  or use  correction  fluid or tape  on the original.  
Data reported  in the eCRF  should be  consistent  with the  data collection  form/source  documents  or 
the discrepancies  should be  documented.  
The sponsor and/or its  designee will provide gui dance to  investigators  on making corrections  to  the 
data collection  forms  and eCRFs.  
15.1. Data  Management Responsibilities  
All data collection  forms  and laboratory  reports  must  be reviewed  by [CONTACT_881675], who will ensure  that they  are accurate  and complete.  AEs must be  graded,  assessed  for 
severity  and causality,  and reviewed by  [CONTACT_7880] [INVESTIGATOR_1461].  Data  collection is  the 
responsibility  of the clinical trial staff  at the site under the  supervision  of the site PI.  During  the 
study,  the investigator must  maintain complete and accurate documentation  for the  study.  
The Emmes  Corporation will serve as  the SDCC for this  study,  and will be responsible  for data 
management,  quality  review,  analysis,  and reporting of the study  data.  
15.2. Data Capture  Methods  
Clinical data (including  AEs,  concomitant medications,  and solicited events data)  will be entered  
into a [ADDRESS_1232636] protection and internal  quality  checks, such  as automatic  range  checks, to  
identify  data that appear  inconsistent, incomplete, or inaccurate.  Clinical data will be entered  
directly  from the data  collection  forms/source  documents.  
15.3. Types  of Data  
Data  for this  study  will include safety,  laboratory  and outcome  measures  (e.g.,  solicited events,  
clinical cure,  and therapeutic  cure).  
15.4. Timing/Reports  
Safety  data will be reviewed  by [CONTACT_881676].  The DSMB  will 
make a  recommendation  at that time  as to the advisabil ity of proceeding  with further  enrollment  or 
use of study  product.  Interim statistical reports  may be generated  as deemed necessary  and 
appropriate  by [CONTACT_122830].  
DMID Protocol No. [ADDRESS_1232637], the  investigator, or  the 
study  site staff.  As a result of deviations,  corrective actions  are to be  developed  by [CONTACT_90478].  
These  practices  are consistent with ICH E6:  
4.[ADDRESS_1232638] be promptly  reported via The Emmes  
Corporation’s  IDES.  
All protocol deviations,  as defined above,  must be addressed  in study  subject data  collection  forms.  
A completed  copy  of the DMID Protocol Deviation  Form must  be maintained in the  Regulatory  
File, as well as in the  subject's  chart.  Protocol deviations  must  be sent to  the local  IRB/IEC per 
their guidelines.  The site principal investigator  [INVESTIGATOR_881609].  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
72  16. PUBLICATION  POLICY  
Following  completion  of the study, the  investigator is  expected  to publish  the results  of this 
research  in a scientific  journal.  The International  Committee  of Medical  Journal Editors  (ICMJE)  
member journals  have adopted a  trials -registration policy  as a condition  for publication.  This 
policy  requires  that all clinical trials  be registered in a public  trials  registry  such as  
ClinicalTrials.gov , which  is sponsored  by [CONTACT_881677].   Other  biomedical  
journals  are considering adopting similar policies.  It is the responsibility  of DMID to register this  
trial in a n acceptable  registry.  Any clinical trial starting  enrollment after [ADDRESS_1232639] relationship  between a 
medical intervention and a  health  outcome.  Studies  designed  for other purposes,  such as  to study  
pharmacokinetics  or major toxicity  (e.g., Phase  I trials),  would  be exempt  from  this policy.  
DMID Protocol No. [ADDRESS_1232640]  MR, Landay  AL, French  AL, Gillevet  PM. Comparison  of 
the diversity  of the vaginal  microbiota  in HIV-infected  and HIV-uninfected  women  with or 
without  bacterial  vaginosis.  The Journal  of infectious  diseases  2008 ; 198:1131 -40. 
 
2. ACOG Practice  Bulletin.  Clinical  management  guidelines  for obstetrician -
gynecologists,  Number  72, May 2006:  Vaginitis. Obstetrics  and gynecology  2006 ; 
107:1195 -206. 
 
3. McCormack  WM,  Jr., Zinner  SH, McCormack WM.  The incidence  of genitourinary  
infections  in a cohort  of healthy  women. Sexually  transmitted  diseases  1994 ; 21:63 -4. 
 
4. Morris  M, Nicoll  A, Simms  I, Wilson  J, Catchpole  M. Bacterial  vaginosis:  a public  
health  review.  Bjog  2001 ; 108:[ADDRESS_1232641]  MB, Copper  RL. Reduced  incidence  of 
preterm delivery  with metronidazole  and erythromycin  in women  with bacterial  vaginosis. 
The New  England  journal  of medicine  1995 ; 333:1732 -6. 
 
6. Hillier  SL, Nugent  RP, Eschenbach  DA, et al.  Association  between  bacterial  vaginosis  and 
preterm delivery of a low-birth-weight  infant.  The Vaginal  Infections  and Prematurity  Study  
Group. The New  England  journal  of medicine  1995 ; 333:[ADDRESS_1232642]  of early  oral clindamycin  on late 
miscarriage  and preterm  delivery in asymptomatic  women  with abnormal  vaginal  flora and 
bacterial  vaginosis:  a randomised  controlled  trial. Lancet  2003 ; 361:983 -8. 
 
8. Donders G. Diagnosis  and management of bacterial  vaginosis  and other types  of abnormal  
vaginal  bacterial  flora: a review.  Obstet Gynecol  Surv  2010 ; 65:462 -73. 
 
9. Workowski  KA, Berman  S. Sexually transmitted  diseases  treatment  guidelines,  2010. MMWR  
Recommendations  and reports  : Morbidity  and mortality  weekly  report Recommendations  and 
reports  / Centers  for Disease  Control  2010 ; 59:1-110. 
 
10. Amsel  R, Totten  PA, Spi[INVESTIGATOR_881610], Chen  KC, Eschenbach  D, Holmes  KK. Nonspecific  
vaginitis.  Diagnostic  criteria  and microbial  and epi[INVESTIGATOR_881611].  The American  journal  
of medicine  1983 ; 74:14 -22. 
 
11. Nugent RP, Krohn  MA, Hillier  SL. Reliability  of diagnosing  bacterial  vaginosis  is improved  
by a standardized  method  of gram stain  interpretation.  Journal  of clinical  microbiology  1991 ; 
29:297 -301. 
 
12. Forsum U, Jakobsson  T, Larsson  PG, et al.  An international  study  of the interobserver  
variation  between  interpretations  of vaginal  smear criteria  of bacterial  vaginosis.  APMIS  2002 ; 
110:[ADDRESS_1232643] 2004 ; 80:8-11. 
 
14. Pechous  R, Ledala  N, Wilkinson BJ, Jayaswal  RK. Regulation  of the expression  of cell wall 
stress  stimulon  member  gene  msrA1  in methicillin -susceptible  or -resistant Staphylococcus  
aureus. Antimicrobial  agents  and chemotherapy  2004 ; 48:[ADDRESS_1232644]  agents  on eukaryotic  cells. Biochemistry  2006 ; 45:2387 -97. 
 
16. Projan  SJ, Brown -Skrobot S,  Schlievert  PM, Vandenesch  F, Novick  RP. Glycerol  
monolaurate  inhibits  the production  of beta-lactamase, toxic  shock  toxin -1, and other  
staphylococcal  exoproteins  by [CONTACT_881678]. Journal  of bacteriology  1994 ; 
176:[ADDRESS_1232645]  of glycerol  monolaurate  
on bacterial  growth  and toxin  production.  Antimicrobial  agents  and chemotherapy  1992 ; 36:626 - 
31. 
 
18. Vetter  SM, Schlievert  PM. Glycerol  monolaurate  inhibits  virulence  factor  production  
in Bacillus  anthracis. Antimicrobial  agents  and chemotherapy  2005 ; 49:1302 -5. 
 
19. Witcher  KJ, Novick  RP, Schlievert  PM. Modulation  of immune  cell proliferation  by 
[CONTACT_881679].  Clinical  and diagnostic  laboratory  immunology  1996 ; 3:10-3. 
 
20. Li Q, Estes  JD, Schlievert  PM, et al. Glycerol  monolaurate  prevents  mucosal  SIV 
transmission. Nature  2009 ; 458:1034 -8. 
 
21. Fichorova  RN, Tucker  LD, Anderson  DJ. The molecular  basis  of nonoxynol -9-induced  
vaginal  inflammation  and its possible  relevance  to human  immunodeficiency  virus  type 1 
transmission.  The Journal  of infectious  diseases 2001 ; 184:418 -28. 
 
22. Galvin  SR, Cohen  MS. The role of sexually transmitted  diseases  in HIV transmission. Nat  
Rev Microbiol  2004 ; 2:33-42. 
 
23. Laga  M, Manoka  A, Kivuvu  M, et al. Non -ulcerative  sexually  transmitted  diseases  as risk 
factors  for HIV-1 transmission  in women:  results  from  a cohort study.  AIDS  1993 ; 7:95 -102. 
 
24. Plummer FA. Heterosexual  transmission  of human  immunodeficiency  virus  type 1 (HIV):  
interactions  of conventional  sexually  transmitted  diseases,  hormonal  contraception  and HIV-1. 
AIDS  Res Hum  Retroviruses  1998 ; [ADDRESS_1232646]  1:S5-10. 
 
25. Schlievert  PM, Peterson  ML. Glycerol  monolaurate  antibacterial  activity  in broth  and 
biofilm  cultures.  PloS one 2012 ; 7:e40350.  
 
26. Petschow  BW, Batema  RP, Ford  LL. Susceptibility  of Helicobacter  pylori  to 
bactericidal  properties  of medium -chain  monoglycerides  and free fatty acids.  Antimicrobial  
agents  and chemotherapy 1996 ; 40:302 -6. 
 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
75  27. Boyle  E, German  JB. Monoglycerides  in membrane  systems. Crit Rev  Food  Sci Nutr 1996 ; 
36:785 -805. 
 
28. Seventeenth  Report of the Joint  FAO/WHO  Expert  Committee  on Food  Additives  Wld 
Hlth Org Techn  Rep Ser 1974,  No 539. Vol. 53, 1974 . 
 
29. Strandberg  KL, Peterson  ML, Lin YC, Pack  MC, Chase  DJ, Schlievert PM.  Glycerol  
monolaurate  inhibits  Candida  and Gardnerella  vaginalis  in vitro  and in vivo but not Lactobacillus.  
Antimicrobial  agents  and chemotherapy  2010 ; 54:597 -601. 
 
30. Schlievert  PM, Strandberg  KL, Brosnahan  AJ, et al. Glycerol  monolaurate  does not alter  
rhesus  macaque  (Macaca  mulatta) vaginal  lactobacilli  and is safe for chronic  use. Antimicrobial  
agents  and chemotherapy  2008 ; 52:4448 -54. 
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
76  SUPPLEMENTS/APPENDIC ES 
APPENDIX  A: SCHEDULE OF  EVENTS  
Table  5: Schedule of Events  
 
Early  Termination  
Unscheduled   Visit 1  Visit 2  Visit 3  
 
Day 1  8 
(Window 
Days  8- 
15) 28 
(Window 
Days  22- 
31) 
Informed  Consent  X     
Inclusion/Exclusion  X     
Demographics  X     
Medical  History1 X     
Concomitant Medication  X X X X X 
Intercurrent  Medical  History2  X X X X 
Physical  Exam  X     
Targeted  Physical  Exam   {X} {X} {X}  
Urine  Pregnancy Test  X     
Gynecological  Exam3 X X X X X† 
Vaginal  Swabs  for Nugent Score,  bacterial/fungal  cultures, 
trichomonas  testing  and appropriate  samples for 
gonorrhea,  
chlamydia  testing4  
X  
X  
X  
X  
X† 
Vaginal  Swab  for Future  Use (if subject  consents  to future  
use sample  collection)  X X X X  
Randomization  X     
Study Drug  Administration  X     
Distribute  Memory Aid  and Study Drug  Kit X     
Counsel  on intravaginal  products,  objects,  sexual  
intercourse,  and pregnancy  avoidance   
X  
X    
Safety Labs  X X X^ X  
Telephone  Contact  [CONTACT_881680]  [X]     
Review  Vaginal  Symptomology  X X X X X 
Review  for insertion  of intravaginal  products,  objects, and  
sexual  intercourse   X X X  
Review Memory Aid  and Collect Study Drug  Kit  X X+ X  
Assessment  of Clinical  Cure   X X X  
Assessment  of Therapeutic  Cure   X X X  
AE/SAE  X X X X* X 
 
1 Include  menstrual, contraceptive, sexual  history  and history  of previous  epi[INVESTIGATOR_881612].  
2 Include  use of intravaginal  products  or objects,  sexual  intercourse, treatment for  vaginitis  (other  than the study  product).  
3 Evaluate  cervix,  vagina,  and vulva.  Perform  Vaginal  pH, Saline  Wet Mount, KOH  Wet Mount, “Whiff  Test”.  
DMID Protocol No. [ADDRESS_1232647] vaginal swabs  for study  specific tests  (gram  stain,  cultures  for bacterial flora  and yeast)  and trichomonas  OSOM testing  (if saline  wet 
mount  is negative, Visit  1 only)  and institution  specific samples  for culture  or molecular  testing  for Chlamydia,  Neisseria  gonorrheae.  (Visit 1 
only). Samples for  gonorrhea  and chlamydia  testing  will be consistent with  standard  of care  at the  institution).  
[ADDRESS_1232648]  at 
home  on Day 2 and Day 3. 
6 Safety  Laboratories  Include:  White blood  cell count, hemoglobin, platelet count,  absolute  neutrophil count, creatinine, ALT,  AST,  total 
bilirubin, random  glucose,  HIV test (Visit  1 only) . 
{ } Targeted  physical examination  if indicated  based  on review  of symptoms.  
[ ] Subjects  will be called  regarding  grade  [ADDRESS_1232649]. 
Subjects  with positive  HIV,  chlamydia  or gonorrhea  tests will be contact[CONTACT_881681].  
+ Memory  Aid will be reviewed  only if solicited  events  continued  at Visit  2. Study  Drug  Kit returned  only if not returned  at Visit 2.  
* If subject  declines to return  for an in-person  visit, the  study  personnel  will ask to contact [CONTACT_881682]/SAEs  on 
Day 22-31. 
† Evaluate  cervix,  vagina,  and vulva.  Collect appropriate  clinical samples for  genital infectious  pathogens.  
# Assess  for vaginal  discharge  (quantity, color,  odor, and  consistency)  and record  presence  or absence  of objective  signs  of 
inflammation  of cervix,  vagina,  and vulva  (edema,  erythema,  excoriation).  
^ Laboratory  abnormalities  that occurred  between  Visit  1 and Visit 2 or worsened  at Visit  2 should  be repeated  until resolved  or has stabilized.  
Further  testing  beyond  Visit 3 is at the discretion  of the  PI [INVESTIGATOR_881613].  
DMID Protocol No. 12 -0021   Version  8.0 23May2017  
78   
APPENDIX B:  Toxicity  Table  
Table  6: Toxicity Table  
HEMATOLOGY  Mild  (Grade 1) Moderate  (Grade 2) Severe  
(Grade 3) 
Hemoglobin  (Female) - g/dL 11.0-11.5 9.5-10.9 <9.5 
WBC  Increase  - cell/mm3  11,001 - 
15,000  15,001 -20,000  >20,000  
WBC  Decrease  - cell/mm3  2,500 -3,500  1,500 -2,499  <1500  
Platelets  Decreased  - cell/mm3  120,000 - 
130,000  100,000 - 
119,999  <100,000  
Neutrophils  Decrease - cell/mm3  1,500 -1,799  1,000 -1,499  <1000  
    
CHEMISTRIES     
Glucose  – Hypoglycemia mg/dL  60-64 55-59 <55 
Glucose  – Hyperglycemia  Random  – mg/dL  140-159 160-200 >200  
Creatinine  – mg/dL  >ULN -1.7 1.8-2.0 >2.[ADDRESS_1232650]  U/L 44-105 106-175 >175  
ALT  U/L 34-105 106-175 >175  
Bilirubin (serum total) mg/dL  1.3-2.0 2.1-2.5 > 2.5 
    
DMID Protocol No. 12 -0021   Version  8.0 23May2017   
79  APPENDIX C:  Female  Genital Grading  Table for  Physical  Exam  Findings  
Table  7: Female Genital Grading Table for Physical Exam Findings  
Parameter  Grade  1 Mild  Grade  2 Moderate  Grade  3 Severe  
Vulvar Edema  Mild, non -pi[INVESTIGATOR_881614], 1 -2+ pi[INVESTIGATOR_881615]  3+ pi[INVESTIGATOR_86785], severe  
enough  to require  urinary  
drainage,  or weepi[INVESTIGATOR_881616]  
+/- skin breakdown  
Vulvar Erythema  Erythema  covering  less than 
50% of vulvar surface  Erythema  covering  50% or 
more  of vulvar  surface  NA 
Vulvar Lesions  Blisters,  ulcerations,  
pustules - no treatment  
indicated  Blisters,  ulcerations or  
pustules, with  treatment  
indicated  Severe  epi[INVESTIGATOR_881617] -moderate  engorgement  Loss of ruggae  and friability  NA 
Vaginal  Erythema  Erythema  covering  less than 
50% of vaginal  surface  Erythema  covering  50% or 
more  of the  vaginal  surface  NA 
Vaginal  Discharge  Mild  increase  in amount  Moderate  - significant  
increase  in amount with  
pooling  in vagina  on 
examination  NA 
Vaginal  Abrasions or  
lacerations  Superficial  disruptions and  
disruptions  extending  
through  the mucosa  with 
minimal  impact  on life Large disruptions  extending  
through  the mucosa  or large  
superficial  disruptions,  
hospi[INVESTIGATOR_881618],  
hospi[INVESTIGATOR_881619] 
50% of cervix  Erythema  covering  50% or 
more  of cervix  NA 
Cervical  Lesions  Blisters,  ulcerations,  or 
pustules, no  treatment  
indicated  Blisters,  ulcerations or  
pustules  with treatment  
indicated  NA 
 
 